Rockefeller University

Digital Commons @ RU
Student Theses and Dissertations

2018

The Role of Neuronal Pentraxin 1 in Promoting
Pancreatic Cancer Progression
Yuehyi Gloria Wu

Follow this and additional works at: https://digitalcommons.rockefeller.edu/
student_theses_and_dissertations
Part of the Life Sciences Commons

THE ROLE OF NEURONAL PENTRAXIN 1 IN PROMOTING
PANCREATIC CANCER PROGRESSION

A Thesis Presented to the Faculty of
The Rockefeller University
in Partial Fulfillment of the Requirements for
the degree of Doctor of Philosophy

by
Yuehyi Gloria Wu
June 2018

© Copyright by Yuehyi Gloria Wu 2018

THE ROLE OF NEURONAL PENTRAXIN 1 IN PROMOTING PANCREATIC
CANCER PROGRESSION

Yuehyi Gloria Wu, Ph.D.
The Rockefeller Unviersity 2018
Pancreatic cancer is a deadly malignancy because it is usually diagnosed at an
advanced stage and does not respond to the majority of treatments. More than
80% of patients present with advanced stage disease at the time of diagnosis and
metastatic pancreatic cancer has a median survival of eight to eleven months
under current standard of care. In the United States, pancreatic cancer is the
fourth leading cause of cancer death. Efforts in using targeted agents to treat
pancreatic cancer have mostly been fruitless. The dismal survival outcome of this
disease and lack of success in clinical trials indicate the necessity for new models
and improved approaches toward therapies. Understanding the cellular and
physiological basis of metastatic pancreatic cancer is therefore of great interest to
the medical and scientific community with regard to developing new targeted
therapies and diagnostic biomarkers.

The first part of this thesis describes the establishment of two complementary
pancreatic cancer metastasis

mouse models using in vivo selection of liver-

metastatic pancreatic cancer cells from their poorly metastatic parental
population. The first mouse model utilized a xenograft system, and the second

model used a syngeneic system. Transcriptomic profiling was used to identify
genes that were differentially expressed between the in vivo selected, highly
metastatic cells and their poorly metastatic parental population in both mouse
models. This approach identified Neuronal Pentraxin 1 (NPTX1) as a potential
metastasis promoter because it was highly expressed in the in vivo selected,
highly metastatic cancer cells compared to the poorly metastatic parental cells.

Through in vivo functional assays, NPTX1 was found to promote pancreatic
cancer progression. NPTX1 was necessary to promote progression of established
liver macro-metastases, a rate limiting step in the metastasis cascade. The second
part of this thesis presents mechanistic studies that describe NPTX1’s role in
promoting cancer cell proliferating under a hypoxic tumor microenvironment.
This proliferation advantage allows cancer cells to survive both in the primary
tumor and promotes distal organ metastatic colonization.

The final part of this study reveals NPTX1 to be clinically relevant in patient
samples. NPTX1 was found to be expressed in pancreatic tumor samples, but not
in healthy pancreatic tissues. In addition, NPTX1 could be detected in the plasma
of the xenograft mouse model, demonstrating the diagnostic and therapeutic
potential of this secreted protein in pancreatic cancer.
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Chapter I Introduction
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Pancreatic adenocarcinoma is a deadly malignancy with a dismal median
survival of less than one year. Metastasis is the primary cause of death in
pancreatic cancer and most patients present with or will eventually develop
metastatic disease. My project presents an effort to identify regulators of
pancreatic cancer metastasis that can be therapeutically targeted. Both xenograft
and syngeneic mouse models were used to in vivo select for pancreatic cancer
cells that are highly metastatic compared to their parental cell line.
Transcriptomic profiling was performed comparing the gene expression of the
highly metastatic sub-lines to the parental cells with the aims of: 1) identifying
novel genes that regulate metastatic colonization of pancreatic cancer, 2)
characterizing the cellular and molecular mechanisms utilized by these genes in
metastatic colonization, and 3) determining the clinical relevance, therapeutic
potential, and diagnostic value of these metastasis regulating genes.

Epidemiology, causes, and prognosis
Pancreatic ductal adenocarcinoma is a deadly disease because it is usually
diagnosed at an advanced stage and does not respond to current treatments.
Worldwide, the incidence of all types of pancreatic cancer (85% of all the
pancreatic tumors are adenocarcinomas) ranges from 1 to 10 cases per 100,000
people (Torre et al., 2015). Pancreatic ductal adenocarcinoma is the most common
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malignancy of the pancreas and this tumor (commonly and here referred to as
pancreatic cancer) presents a substantial health problem. In the United States,
each year about 43,000 patients die from pancreatic cancer and it is the fourth
leading cause of cancer death. If the outcomes are not improved, the disease is
predicted to be the second leading cause of cancer-related mortality within the
next decade (Rahib et al., 2014).

More than 80% of patients present with advanced stage disease at the time of
diagnosis (Stathis and Moore, 2010) and metastatic pancreatic adenocarcinoma
has a median survival of eight to eleven months under current standard of care
(Ryan et al., 2014). Efforts in using other agents to treat pancreatic cancer have
mostly been fruitless and more than twenty Phase III clinical trials have failed
(Ryan et al., 2014). The dismal survival outcome of this disease and lack of
success in clinical trials indicates the necessity for new models and improved
approaches toward therapies.

There are several risk factors and established genetic syndromes associated with
pancreatic adenocarcinoma. Age is the major determinant of pancreatic cancer
with most patients diagnosed at >50 years of age with peak incidence in the
seventh and eighth decade of life. Risk factors associated with pancreatic
adenocarcinoma include: smoking (Bosetti et al., 2012), long-standing diabetes
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mellitus (Ben et al., 2011), obesity (Aune et al., 2012), and chronic pancreatitis
(Duell et al., 2012). Genetic syndromes and associated genes include: hereditary
pancreatitis (PRSS1, SPINK1) (Rebours et al., 2008), familial atypical multiple
mole and melanoma syndrome (p16) (Vasen et al., 2000), and hereditary breast
and ovarian cancer syndromes (BRCA1, BRCA2, PALB2) (Iqbal et al., 2012)
(Jones et al., 2009). Although it is estimated that 5 to 10% of pancreatic cancers
have an inherited component, the genetic basis for familial aggregation has not
been identified in most cases (Klein et al., 2004; Roberts et al., 2016). Presently, in
most cases of pancreatic adenocarcinoma, the causes of the disease are unknown.

Pancreatic cancer carries an extremely poor prognosis for several reasons. First, it
is usually diagnosed at an advanced stage due to the lack of specific symptoms
and lack of early detection methodologies inherent to other cancer types. Such
early detection approaches include mammograms for breast cancer and
colonoscopy for colon cancer. Second, pancreatic cancer is aggressive with early
metastatic spread. Third, most pancreatic cancer is largely resistant to all current
therapies including chemotherapy, radiotherapy, and molecularly targeted
therapy. Finally, pancreatic cancer harbors multiple genetic and epigenetic
alterations and has a complex and dense microenvironment. These factors
contribute to the dismal overall 5-year survival rate of <7%. Almost all patients
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who survive past 5 years are the 10-20% of patients who are qualified and have
undergone surgical resection. The 5-year survival rate in this subgroup of
patients is 15-25% (He et al., 2014).

Biological features and pathophysiology
The defining features of pancreatic adenocarcinoma include a very high rate of
activating mutations in KRAS (>90%), progression from distinct types of
precursor lesions, local invasion and distant metastasis, extensive stroma
(desmoplasia) leading to hypovascularity and a hypoxic microenvironment,
reprogramming of the cellular metabolism, and immune suppression.

Molecular carcinogenesis
Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia
(PanIN) but can also arise from other precursor lesions such as intraductal
papillary mucinous neoplasms and mucinous cystic neoplasms (Tanaka, 2014;
Ying et al., 2016). PanIN are microscopic premalignant pancreatic lesions
associated with the pancreatic ducts harboring the signature mutations of
pancreatic cancer. Like the stepwise model from polyp-to-adenocarcinoma
established in colon cancer, pancreatic intraepithelial neoplasia progresses from
low grade to high grade in types 1, 2, and 3. They are associated with
accumulating genetic alterations.
!5

Pancreatic cancer exhibit altered autocrine and paracrine signaling cascades that
promotes cell proliferation and metastasis. Many signaling molecules such as
transforming growth factor-a (TGF-a), insulin-like growth factor 1 (IGF 1),
fibroblast growth factors (FGFs) and hepatocyte growth factors (HGH) and their
respective receptors such as epidermal growth factor (EGFR), receptor tyrosineprotein kinase erbB-2 (HER2), HER3, IGF1 receptor (IGF1R), FGF receptors
(FGFRs), and HGF receptors (HGFR) activate multiple pathways to enhance
carcinogenesis and metastasis (Preis and Korc, 2011). In addition, pancreatic
cancer cells also activate pro-survival and anti-apoptotic pathways such as signal
transducer and activator of transcription 3 (STAT3), nuclear factor-kB (NF-kB)
and AKT. Many genes such as WNT and NOTCH that are typically activated
during development are also activated in pancreatic cancer.

Mutational landscape
More than 90% of all pancreatic cancer cases have activating KRAS mutations,
and these mutations are already present at the earliest stage of PanIN (Kanda et
al., 2012). Inactivating mutations of TP53, CDKN2A, and SMAD4 occur in
50-80% of pancreatic cancers and are detected with increasing frequency in type 2
and 3 lesions of PanIN. This suggests that KRAS mutations contribute to the
initiation of tumor and the subsequent mutations in TP53, CDKN2A, and
!6

SMAD4 occur as the tumor progresses (Hustinx et al., 2005). While point
mutations of individual genes reveal many aspects of the disease
pathophysiology, other types of genomic events also contribute to carcinogenesis.
These genomic events include epigenetic modifications, deletions, and copy
number alterations. For example, CDKN2A is commonly inactivated by DNA
methylation, and CDKN2A and SMAD4 are commonly inactivated through
homozygous deletion. Unfortunately, no therapy targeting KRAS, TP53,
CDKN2A, and SMAD4 has been approved for the treatment of pancreatic cancer.

Microenvironment
One defining hallmark of pancreatic cancer is its dense collagenous stroma
(desmoplasia) (DuFort et al., 2016; Seymour et al., 1994). The pancreatic cancer
stroma is composed of both extracellular matrix (ECM) protein components and
cellular elements. Other factors in the stroma that may interact with cancer cells
include growth factors that can directly contribute to the survival of tumor cells
(Neesse et al., 2013). The cellular elements of the stroma include proliferating
myofibroblasts (also referred to as cancer-associated fibroblasts) that produce the
collagenous matrix. The precursors of these myofibroblasts in the pancreas are
the pancreatic stellate cells and in the case of liver metastasis, the precursors of
the myofibroblasts are the hepatic stellate cells. An active bi-directional
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interaction between the stromal stellate cells and cancer cells has been
demonstrated (Apte et al., 2013; Ohlund et al., 2017). In addition, the stromal
stellate cells can also contribute to immune evasion in pancreatic cancer by
sequestering tumor-suppressive CD8+ T cells (Ene-Obong et al., 2013) and
promoting action of myeloid-derived suppressor cells—an immunosuppressive
innate immune cell population (Mace et al., 2013).

Although multiple studies have indicated a facilitating role for stromal stellate
cells in progression and metastasis of pancreatic cancer, several studies using
genetic techniques (Lee et al., 2014; Ozdemir et al., 2014) or signaling pathway
inhibition (Rhim et al., 2014) have shown the opposite effect. It is likely that the
stroma has context and timing dependent roles in pancreatic cancer.

Other cell types infiltrating the pancreatic tumor stroma include immune cells,
endothelial cells, and neuronal cells. The immune cells include T cells, myeloidderived suppressor cells and macrophages. The immune cell infiltrates in
pancreatic cancer closely resemble an immunosuppressive phenotype which
restricts immune surveillance and at the same time creates an inflammatory
program that supports tumorigenesis. This immunosuppressive phenotype is
observed both in early and late stage of the cancer (Amedei et al., 2014; Inman et
al., 2014). From earliest stage of tumor formation, immunosuppressive regulatory
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T cells and Gr1+CD11b+ myeloid cells (myeloid-derived suppressor cells) are
recruited to the stroma leading to a blockage of T-cell mediated anti-tumor
immunity. In addition, macrophages with tumorigenic potentials are recruited to
early and advanced lesions (Lesina et al., 2011).

The microenvironment has many indirect effects on disease progression.
Pancreatic tumors possess low microvascular density, leaky vasculature, limited
profusion, and intramural hypoxia. The dense and fibrous stroma can potentially
contribute to the reduced blood flow and the high interstitial pressure that has
been hypothesized to impair drug delivery ( Provenzano et al., 2012). This dense
extracellular matrix results in an extremely hypoxic environment for cancer cells.
In one study, physicians measured the oxygen tension in clinically resected
pancreatic cancer and found the tumors to be extremely hypoxic (Koong et al.,
2000) with oxygen tensions ranging from non detectable to 5.3 mm Hg. In
comparison, the normal pancreatic tissue had oxygen tensions ranging from 24.3
mmHg to 92.7 mmHg in the same study.

Metabolic alterations
Pancreatic cancer is characterized by a severely hypoxic and nutrient-deprived
microenvironment. Consequently the cancer cells must contend with this severe
metabolic stress and a number of acquired alterations in nutrient acquisition and
!9

use are required for the growth and survival of pancreatic cancer cells (Erkan et
al., 2009). Many of these adaptive mechanisms by pancreatic cancer cells are
driven by oncogenic KRAS and hypoxia-inducible transcription 1α (HIF1α). For
example, oncogenic KRAS directly and indirectly promotes acquisition of
extracellular nutrients such as increased glucose uptake, and directs the
scavenging of serum lipids and proteins by an endocytic mechanism,
macropinocytosis (Commisso et al., 2013). Oncogenic KRAS can also
constitutively drive high level of autophagy to provide intermediate metabolites
for biosynthesis and energy production (Yang et al., 2011).

Current therapeutic interventions
The majority of patients present with locally advanced and unresectable disease
because of metastasis most commonly to the liver and peritoneum or vascular
involvement. Fewer than 20% of patients have resectable disease, and 80% of
patients who have undergo surgery and adjuvant treatment will relapse and
ultimately die of the disease. While surgery is the only potential cure to the
disease, the outcomes of patients treated with surgery are poor. Gemcitabine was
first approved in 1997 by the FDA based on a randomized trial comparing
gemcitabine with 5-fluorouracil. The clinical benefit achieved was symptom
improvement and a modest survival benefit (Burris et al., 1997). In 2011, a
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combination of folinic acid (leucovorin), 5-fluorouracil, irinotecan and
oxaliplatinum (FOLFIRINOX) demonstrated improved overall and progression
free survival benefits compared to gemcitabine monotherapy (Conroy et al.,
2011). In 2012, gemcitabine and albumin bound paclitaxel showed improved
efficacy compared to gemcitabine monotherapy and was approved by the FDA
(Von Hoff et al., 2013). Currently, FOLFIRINOX and gemcitabine–nab-paclitaxel
are considered standard treatment for patients who have good performance
status and are more likely to tolerate the side effects of either treatments. To date,
there has not been a widely adopted targeted treatment against pancreatic cancer.

Biomarkers for diagnosis and screening
The most widely used biomarker in pancreatic cancer is serum cancer antigen
19-9 (CA 19-9). CA19-9 lacks sensitivity or specificity to be useful for early
detection of pancreatic cancer, but it is currently used to monitor disease
progression (Ballehaninna and Chamberlain, 2012). A more sensitive and specific
biomarker is needed to help in early detection of the disease and increase the
number of patients who qualify for curative surgery.

Pancreatic cancer metastasis
Many factors contribute to the difficulty in treating pancreatic cancer. Most
importantly, unlike cancers such as breast or colorectal cancer where many
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patients are diagnosed at an early stage and can be treated by locally resecting
the primary tumor, most pancreatic cancer patients present with advanced
metastatic disease (Oberstein and Olive, 2013). Thus, in additional to developing
effective screening methods, targeting metastasis is essential in treating
pancreatic cancer.

Metastasis is the multi-step process of cancer cells breaking away from the
primary tumor to enter the blood stream (intravasation), surviving in the blood
circulation, arriving at a distal organ (extravasation) where the cancer cells must
adopt specific phenotypes and mechanisms to survive in a foreign environment
as micro-metastases, and proliferating into macro-metastases (colonization)
(Gupta and Massague, 2006). The last step in cancer metastasis: colonization of
the distal organ is hypothesized to be the rate-limiting step in metastasis, since
large numbers of micro-metastases can form but will not develop into clinically
significant macro-metastases (Hanahan and Weinberg, 2011). This hypothesis is
supported by the case of colorectal cancer where resection of liver macrometastasis can lead to long term survival (Fong et al., 1999), even though many
tumor cells are likely to reach the liver and form dormant micro-metastasis
(Taylor, 1996). Therefore, an ideal therapy against metastasis should target the
rate-limiting colonization step to prevent or halt metastasis progression.
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Metastasis has been hypothesized to occur early in pancreatic cancer. Clinical
observations that patients with small or undetectable primary tumor still have
high chance of metastasis and the common occurrence of metastasis after
complete resection of the primary tumor supports this view (Tuveson and
Neoptolemos, 2012). A recent study using a mouse genetic model to lineage trace
pancreatic cancer cells also supports this hypothesis. In this mouse genetic
model, micro-metastases in the liver are observed before the occurrence of
invasive pancreatic cancer (Rhim et al., 2012). Circulating tumor cells were also
observed in mice with pre-invasive pancreatic cancer (Rhim et al., 2012). Another
study utilizing clinical imaging, autopsy data, and mathematical modeling
approaches also predicted that most patients will have micro-metastases at the
time of diagnosis even when the orthotopic tumor is relatively small (Haeno et
al., 2012).

If most pancreatic cancer patients present with, or eventually will develop
metastatic disease, therapies that target the primary tumor would only be
palliative and the disease will progress rapidly. There is a lack of targeted
therapy in pancreatic cancer that is able to effectively control metastatic
progression, such as Herceptin for breast cancer (Slamon et al., 2001). Thus, there
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is a great need to understand the molecular mechanism of PDAC metastasis and
to design screening methods and novel therapies that are effective in suppressing
metastatic progression, specifically at the rate-limiting, colonization step.

Experimental models
There are several widely used pancreatic cancer model systems in vivo. These
experimental models have yielded important insight into pancreatic cancer
pathophysiology. Experimental models used in this thesis include: traditional
cancer cell lines, xenograft models (Caldas et al., 1994) and genetically
engineered mutant mice (GEMM) syngeneic models (Aguirre et al., 2003; Guerra
et al., 2007; Hingorani et al., 2003; Hingorani et al., 2005).

Syngeneic mouse model of pancreatic cancer tumorigenesis and metastasis
Mouse models of pancreatic cancer introduce the most frequently found human
pancreatic cancer mutant alleles into the mouse pancreas. These GEMM models
have confirmed the causative roles for many mutant gens previously identified in
human pancreatic cancer genomes. For example, GEMM models have revealed
the causative role of oncogenic KRAS to be sufficient to initiate PanIN and these
mice spontaneously progress to locally invasive and metastatic pancreatic cancer
closely resembling the human disease. Additional mutations in the canonical
tumor suppressor genes that are also frequently found in clinical pancreatic
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cancer genomes, such as CDKN2A, TP53, or SMAD4 have been shown to
accelerate tumor progression with distinct histologies. The most widely used
GEMM to study pancreatic cancer is with oncogenic Kras and mutant Tp53, and
is referred to as the Kras LSL.G12D/+; p53 R172H/+; Pdx Cre tg/+ (KPC) mouse
for the rest of the thesis.

One limitation of the GEMM is the cost and timeframe to develop and maintain
the required mouse colony. Syngeneic mouse model using GEMM derived cancer
cell line ( Torres et al., 2013) allografted into a syngeneic mouse is one potential
solution. This KPC syngeneic mouse model allows the study of the metastatic
cascade under an immuno-competent background.

Xenograft model of pancreatic cancer metastasis
In order to study pancreatic cancer metastasis in vivo with human pancreatic
cancer cells, xenograft mouse models in which cells are implanted or injected
into immunodeficient mice are developed. Depending on the stage(s) of the
metastatic cascade that are under investigation, investigators have transplanted
or inoculated cells into mice at various sites (Loo et al., 2015).

Besides inoculation of pancreatic cancer at orthotopic sites (Kim et al., 2009),
direct introduction of pancreatic cancer cells into the circulation can be
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performed through portal vein injection or intrasplenic injection, both of which
result in dissemination of pancreatic cancer cells into the portal circulation and
into the liver parenchyma. Compared to intra-pancreatic injection, these
procedures bypass the earlier stages of the metastatic cascade such as invasion of
the primary tumor and intravasation into the circulation. Instead, survival of
pancreatic cancer cells in the circulation and later stages are examined.

Regardless of which stage of the metastatic cascade is under investigation,
xenograft models of cancer metastasis have proven of great utility in delineating
the mechanisms involved in metastasis as in vivo modeling of cancer progression
can provide insights that are not readily apparent in in vitro systems. A criticism
of xenograft models of human cancer cell metastasis is that immunodeficient
mice are used, which could not provide any information on interactions between
the immune system and cancer cells. Thus, complimenting the xenograft model
with the syngeneic mouse model will allow investigation into mechanisms that
are crucial in the human disease yet account for the immune components.

In vivo selection
In vivo selection of cancer cells is a technique pioneered by Fidler and colleagues
in 1973 (Fidler, 1973). It can be utilized to enrich for specific cell populations with
desired phenotypes from more heterogeneous populations. Within the context of
cancer biology, in vivo selection had been utilized to select for breast cancer cells
!16

with enhanced capacity for lung, bone and brain metastasis. Transcriptomic
profiling and mechanistic studies comparing the parental heterogeneous breast
cancer population and the in vivo selected organ-metastatic sub-lines had
resulted in the identification of genes that regulate metastasis to the respective
organs by breast cancer cells (Kang et al., 2003; Minn et al., 2005; Png et al., 2011;
Tavazoie et al., 2008). More recently, in vivo selection was performed with
melanoma cells and mediators of melanoma metastasis to the lungs were
identified (Pencheva et al., 2012) as well as with colon cancer cells and promoters
of colon cancer metastasis were also identified (Loo et al., 2015). Similar cellular
phenotypes were identified in breast and melanoma cancer cells that were in vivo
selected for lung colonization capacity, although different genes and pathways
were utilized in breast cancer and melanoma respectively. This highlights the
possibility that with regard to organ colonization, there might be common
phenotypes that are selected for irrespective of cancer type. With regard to
pancreatic cancer, an in vivo selection model for liver colonization, the final step
of metastasis has not been yet been demonstrated. Given the utility of in vivo
selection for identifying molecular mediators of breast, melanoma, and colon
cancer metastasis, novel mediators of pancreatic cancer metastasis can be
identified with an appropriate model of liver colonization and in vivo selection.
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Innovation
To date, all approved chemotherapies for PDAC target proliferation of
cancer cells and no targeted therapies are available. Attempts in adopting other
targeted therapies such as Cetuximab (anti-EGFR) or Bevacizumab (anti-VEGF)
have failed in stage III clinical trials (Ryan et al., 2014). Many studies of PDAC
have focused on genes that are frequently mutated such as KRAS, p53, CDKN2A,
and SMAD4. These highly mutated genes play essential roles in tumorgenesis
and cancer progression; however, most of the known highly mutated genes in
pancreatic cancer are tumor suppressors that cannot yet be therapeutically
targeted. Most of the established targeted cancer therapies inhibit tumor
promoters, such as vemurafenib (BRAF inhibition) in melanoma and
trastuzumab (Her2 antibody) in breast cancer. The only widely mutated tumor
promoter in pancreatic cancer, KRAS, has proven to be extremely difficult to
inhibit therapeutically. In addition, while metastasis is the major cause of
mortality in cancer, there has yet to be an approved therapeutic that specifically
targets this step in cancer progression.

This project, which employs a combination of in vivo selection in mouse
xenograft and syngeneic models coupled with transcriptomic profiling, presents
an innovative approach in search for metastatic regulators that can be
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therapeutically targeted. The highly liver-metastatic pancreatic cancer sub-lines
isolated using in vivo selection allow the potential discovery of novel metastasis
pathways that may not be pursued otherwise. Discovery of previously
unexplored genes in the metastasis colonization pathway could also be the first
step in developing targeted therapies in PDAC that can effectively treat
metastatic disease.
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Specific aims
Aim 1. Identify novel genes that regulate metastatic colonization of the liver by
pancreatic cancer
Liver is the most common metastasis site in pancreatic cancer (Yachida and
Iacobuzio-Donahue, 2009) and most gastrointestinal cancers. In order to study
metastatic colonization of the liver by pancreatic adenocarcinoma cells, an in vivo
selection approach was utilized to isolate highly liver-metastatic sub-lines from
the poorly metastatic parental pancreatic cancer cell lines. The highly livermetastatic sub-lines were then compared to the poorly liver-metastatic parental
line by transcriptomic profiling using RNA sequencing. Genes that were
differentially expressed between the highly metastatic sub-lines and the poorly
metastatic parental line were hypothesized to play a significant role in metastatic
colonization. The ability of these candidate genes to modulate metastasis was
then assessed by gain-of-function and loss-of-function experiments in multiple
pancreatic cancer cell lines using the in vivo liver metastatic colonization assay.
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Aim 2. Characterize the cellular and molecular mechanisms utilized by these genes
during metastasis colonization
To understand the molecular and cellular mechanisms employed by the
candidate gene to modulate metastasis in the liver microenvironment, the
cellular phenotypes that were likely to be involved were investigated.

Aim 3. Determine the clinical relevance, therapeutic potential, and diagnostic value of
these metastasis-regulating genes in pancreatic cancer.
To determine whether the candidate gene is expressed by human pancreatic
tumors, the expression of the candidate gene was assessed by qRT-PCR in both
clinical PDAC samples and healthy pancreatic tissues. Potential diagnostic and
therapeutic value of the candidate gene was evaluated.
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Chapter II Materials and Methods
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Animal studies
All animal work was conducted in accordance with a protocol approved by the
Institutional Animal Care and Use Committee (IACUC) at The Rockefeller
University. 5-6 weeks old age-matched male NOD-SCID-GAMMA mice were
used for intrahepatic colonization assays, liver metastatic colonization assays,
pancreatic orthotropic metastasis assays and orthotopic tumor growth assays
involving PANC1, BxPC, MiaPaCa2, KPC, PANC1-LM3 and KPC-LM2 cell-lines.
5-6 weeks old age-matched male B6129SF1/J mice were used for experiments
involving KPC cell line. For all experiments involving anesthesia and surgery,
mice were monitored after surgery to ensure recovery from anesthesia before
returning to clean cages. Breeding pairs of all mice strains were originally
obtained from Jackson Laboratories and bred in house to establish colonies for
experiments, with supplemental purchase from Jackson Laboratories when
necessary.
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In vivo selection

5

5 x 10 PANC1 and KPC cells expressing a luciferase reporter were suspended in

a 20 ul volume of 1:1 PBS/Matrigel mixture and injected directly into the livers of
mice (intrahepatic injection, described in detail below). Pancreatic cancer liver
nodules were allowed to develop over a period of 3-6 weeks and monitored by
bioluminescence imaging. Nodules formed were excised and dissociated by
collagenase and hyaluronidase digestion (described in detail below) into single
cell suspensions. The cells were allowed to expand in vitro before re-injection into
mice. After two to three iterations of in vivo selection, multiple highly metastatic
PANC1-LM3 and KPCLM2 sub-lines were established from nodules obtained
from independent mice. The in vivo selected cells were passaged 5 times in vitro
and were visually checked to contain no murine primary stromal cells before all
downstream analyses.

Intrahepatic injection for in vivo selection and liver colonization
Each mouse was first anesthetized with injection of ketamine/xylazine solution
into the peritoneal cavity. When the mouse was deeply anesthetized (confirmed
by lack of reflex response after pinching of hind legs), the fur above the abdomen
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wall was shaved and the shaved abdomen wall was scrubbed with iodine and
70% alcohol. A 20 mm incision was made through the skin and peritoneum just
below the sternum of the mouse to expose the liver. The left lobe of the liver was
gently pulled out with a forcep and Q-tip, and cells in a 20µL volume of 1:1 PBS/
Matrigel (Corning) mixture were injected slowly using a 28-gauge needle
attached to a 1/2 cc insulin syringe (Becton Dickinson). Blanching and bulging of
the liver at the site of injection without reflux of injected cells indicated a
successful injection. The needle was retracted slowly and a Q-tip placed over the
site of injection with gentle pressure for about 20 seconds to prevent bleeding
and spillage of injected cells. The left lobe was then returned to its original
location using a Q-tip and the peritoneum of the mouse closed with surgical 6-0
sutures (Roboz) and the skin closed with 9mm wound clips (Roboz).

Intrasplenic injection for liver metastatic colonization assays

Each mouse was first anesthetized as described above. The left flank of the
anesthetized mouse was shaved and scrubbed with butadiene and 70% alcohol.
A 10 mm incision was then made in the skin and peritoneum just below the
ribcage of the mouse to expose the spleen. The spleen was gently exteriorized
5

with a pair of forceps and stabilized using a Q-tip. 3-5 x 10 Cells in 50µL volume
of PBS were injected slowly using a 28-gauge needle attached to a 1/2 cc insulin
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syringe. A blanching of the spleen without reflux of injected cells indicated a
successful injection. The needle was retracted slowly and a Q-tip placed over the
site of injection with gentle pressure to prevent bleeding and leakage of the
injected cells. After 30 seconds, the spleen was removed using a cautery and the
peritoneum of the mouse closed with surgical 6-0 sutures (Roboz) and the skin
closed with 9mm wound clips (Roboz).
Pancreatic injection for orthotropic growth and metastasis assays
Each mouse was first anesthetized as described above. The left flank of the
anesthetized mouse was shaved and scrubbed with iodine and 70% alcohol. A 10
mm incision was then made in the skin and peritoneum just below the ribcage

of the mouse to expose the spleen with the pancreas attached. The spleen and
pancreas were gently exteriorized with a pair of forceps and stabilized using a Q5
tip. 5 x 10 Cells in a 20 µL volume of 1:1 PBS/Matrigel mixture were injected
slowly using a 28-gauge needle attached to a 1/2 cc insulin syringe while the
pancreas was stretched by holding the end of the spleen. A bulging of the
pancreas without reflux of injected cells indicated a successful injection. The
needle was retracted slowly and a Q-tip placed over the site of injection with
gentle pressure to prevent bleeding and leakage of the injected cells. The
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pancreas and spleen were returned into the original cavity location and the
peritoneum of the mouse was closed with surgical 6-0 sutures (Roboz) and the
skin was closed with 9mm wound clips (Roboz).

Retro-orbital injection of luciferin and DEVD-luciferin for bioluminescent
imaging
Each mouse was anesthetized using an isoflurane anesthesia chamber. After
anesthesia, the mouse was placed on its left flank and restrained using the thumb
and index finger of the non-dominant hand. At the same time, the index finger
and thumb were used to draw back the skin below the right eye of the mouse.
100µL luciferin substrate (Perkin Elmer) was then injected using a 28-gauge
insulin needle on a 1cc syringe into the retrobulber sinus of the mouse. For in vivo
caspase activity bioluminescent imaging, 100µL of amino-DEVD-luciferin
substrate (15mg/mL) (Promega) was injected for bioluminescent imaging. 5
hours after imaging with DEVD-luciferin, regular luciferin substrate (15mg/mL)
was injected and imaging performed to obtain a normalization signal. The needle
was then retracted slowly and the anesthetized mouse can be placed into the IVIS
imaging system for bioluminescent imaging. Mice were imaged with their

abdomens facing up, at 30s after injection of luciferin and at 5 minute after
injection of DEVD-luciferin. Images were taken with exposure times ranging
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from 5s to 5min dependent on metastatic burden to avoid saturation of the CCD
camera sensor, leading to inaccurate measurements.

Tail vein injection for lung and other distal organ metastasis assay

Intravenous tail vein injection was used to assess the lung and other distal organ
metastatic capability of pancreatic cancer cells. Mice inoculated with pancreatic
cancer cells were randomized for treatment. Each mouse was restrained using a
restrainer (Braintree Scientific) designed for tail vein injection. The tail of the
moue were then gently warmed in 37 degree Celsius water, and wiped with 70%
6
alcohol. 2x 10 pancreatic cancer cells in 100 µL of PBS were injected into the

lateral tail vein of the mouse using a 27 1/2 -gauge needle attached to a 1cc
syringe. A paling of the vein and noticeable delivery of PBS up the tail indicated
a successful injection. The needle was retracted slowly and a kim-wipe was used
to exert gentle pressure on the site of injection to stop the bleeding. The mouse
was released after 30 seconds.
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Subcutaneous injections for in vivo tumor growth assays

6
Each mouse was first anesthetized as described above. 1 x 10 cells were

suspended in 100 µl of 1:1 PBS:Matrigel mixture and injected into the

subcutaneous flanks of the anesthetized mouse using a 27-gauge needle on a 1-cc
syringe. Tumor growth was measured using digital calipers starting 7 days after
injection or whenever the tumor was palpable. Each mouse was anesthetized
using an isoflurane anesthesia chamber. Palpable tumors were then grasped and
measured. Volumes of tumors were calculated using the formula, Volume =
2
(width) x (length)/2.

Liver extraction and tumor nodule extraction

Each mouse was first deeply anesthetized with a lethal dose of ketamine/
xylazine solution. After confirmation of anesthesia from lethal dose of ketamine/
xylazine or death, the abdomen was scrubbed with betadine and 70% ethanol. A
30mm incision was then made and the liver or other tumor nodules exteriorized
using a small tweezer with the help of a Q-tip. The liver of the mouse or other
tumor nodules were then cut free of the abdominal cavity and washed gently
with PBS for three times. It could then be used for downstream experiments.
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Tumor nodule dissociation into cells for culture

Each excised liver metastatic tumor nodule was first washed three times in PBS.
After washing, the tumor nodule was minced up as finely as possible with a pair
number 10 surgical scalpels and re-suspended in 15mL of antibioticssupplemented PBS. The minced tumor nodule was then collected by
centrifugation at 800g for 10 min using 50mL Falcon tubes. The PBS was removed
and the nodule re-suspended in ACK buffer (Lonza) for lysis of residual red
blood cells. After 10 min incubation at room temperature, the minced nodule was
collected by centrifugation at 800g for 10 minutes, and re-suspended in
enzymatic digestion media (300u/mL Collagenase, 0.25mg/mL Hyaluronidase,
24u/mL DNAseI; Worthington Biochemicals) and incubated with gentle
agitation for 2hrs at 37 degree Celsius. After enzymatic digestion, cells were
collected by centrifugation at 800g for 10 minutes. The pellet was re-suspended
and incubated in 5mL trypsin-EDTA for 10min at 37 degree Celsius. After trypsin
digestion, 10mL of D10F was added to stop the digestion and cells were collected
again by centrifugation at 800g for 10 minutes. After the trypsin digestion, the
supernatant was carefully aspirated until at least 5mL of cell culture media was
left in the 50mL Falcon tube. The pellets and remaining media were then
resuspended in 10mL of cell culture media, and filtered successively through
70#m and 40#m cell strainers to remove undigested debris and plated onto
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treated cell culture plates. Freshly plated cells were monitored daily with
exchange of fresh cell culture media for contamination and tested for
mycoplasma contamination before transitioning into routine culture or other
processing such as transcriptomic profiling.

Ex vivo tumor cell sorting from liver metastases in the xenograft model

Immediately following tumor nodule extraction and single cell suspension as
described above, xenografted human tumor cells could be sorted out from the
other contaminating primary mouse cell using flow cytometry. Tumor cell
suspension was centrifuged at 800g for 10 minutes at 4 degree Celsius and
resuspended in 10mL of 22% OptiPrep (Sigma-Aldrich) diluted in regular cell
culture media. Tumor cell suspension in 22% OptiPrep was layered on top of a 10
mL 40% Optiprep, and lastly a 10mL cell culture media was layered on top of the
22% OptiPrep. This density gradient was then centrifuged at 800g for 10 min at 4
degree Celsius. Cells at the 22% OptiPrep and cell culture media interface were
collected. The cells were then washed once with regular cell media and
centrifuged at 800g for 10 minutes at 4 degree Celsius. When the cell pellets

approximately resembled 2-4 x10

6

PANC1 or PANC1 LM3 cells, they were

resuspended in 400uL of FACS buffer (5 mg/mL BSA, 10 mM HEPES, 2.5 uM
EDTA in PBS). 80uL of Mouse Cell Depletion Kit magnetic beads (Miltenyi
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Biotec, 130-104-694) was added to the tumor cell suspension. The tumor cell and
magnetic beads mixture was incubated at 4 degree Celsius for 15 minutes. In the
mean time, 3mL of cold FACS buffer was used to wash the LS Columns (Miltenyi
Biotec, 130-042-401). After the incubation of the magnetic beads with tumor cells,
5mL of cold FACS buffer was added to the magnetic beads and tumor cell
suspension. This mixture was then added to the LS Columns and the flowthrough was collected on ice. Lastly, 1mL of cold FACS buffer was added to the
LS Column to wash out remaining cells. The flow-through was then centrifuged
at 800g for 10 minutes at 4 degree Celsius and the cell number was counted. The
tumor cells were resuspended in 40uL FACS buffer and a mixture of anti-human
HLA conjugated with FITC (eBioscience, 11-9983-42) and anti-mouse IgG2a κ
Isotype conjugated with APC (Biolegend, 116619) antibodies were added with
the ratio of 1uL of each antibody per million cells. The samples were then sent to
the flow-cytometry facility at The Rockefeller University and cells that were FITC
+ and APC- were collected. The collected cells were pure human pancreatic
cancer cells and can be subsequently cultured or analyzed.

!32

Plasma collection from mice

Each mouse was first deeply anesthetized with a lethal dose of ketamine/
xylazine solution. After anesthesia, the chest of the mouse was scrubbed with
betadine and 70% ethanol. The chest cavity of the mouse was then quickly cut
open and the heart exposed. Whole blood was collected from the mouse via
cardiac puncture using a 27-gauge needle attached to a 1cc syringe. Up to 500µL
of blood can be collected. The blood is collected in the lavender top, EDTA coated
tube (BD). Cells were removed from plasma by centrifugation for 10 minutes at
1,000 x g using a refrigerated centrifuge. Collected serum was then aliquoted and
stored at -80 degree Celsius.

In vivo inducible shRNA knock down of NPTX1

PANC1 LM3 cells labeled with the luciferase reporter were transduced with
5
lentivirus carrying the tet-on pLKO-shNPTX1 constructed. 3x10 of the PANC1

LM3 cells transduced with the doxycycline inducible shRNA construct were
injected through the spleen into the liver of 6-week old Nod-Scid-Gamma mice.
The tumor cells were allowed to grow for 7 or 14 days, and the mice were
randomly assigned to two groups. One group receive doxycycline chow and
doxycycline water with glucose, while the other group receive amoxicillin chow

!33

and water with glucose. Both groups receive fresh chow and water every 2 days.
Bioluminescence signal from the liver was measured every 7 days.

Isolation of murine primary hepatic stellate cells

Murine primary hepatic stellate cells were isolated following published protocol
(Mederacke et al., 2015). 10 week old B6 male mice were used for all murine
primary hepatic stellate cell isolation.

Isolation of tumor infiltrating immune cells
Upon excision, tumors were finely minced and incubated in HBSS (Gibco) supplemented
with 2% FCS (HBSS-2), Collagenase 8 at 0.05mg/mL (Sigma), 1mM sodium pyruvate
(Gibco), 25mM HEPES (Thermo Fisher), and DNaseI at 10mg/mL (Roche) at 37C on a
shaker at 80RPM for 30 minutes. The mixture was then thoroughly titrated and passed
through a 70um filter and neutralized with HBSS-2 to dilute the collagenase. Tumorinfiltrating lymphocytes were subsequently purified via density gradient centrifugation
using Percoll (GE Healthcare). Briefly, the cells were resuspended in 35% Percoll and
then 70% Percoll was added to the bottom of the suspension by a glass Pasteur pipette.
The suspension was spun at 2100 RPM for 20 minutes at room temperature with the
brake off. After the spin, the pellet of red blood cells was removed, as well as excess
percoll/buffer, leaving a purified population of tumor-infiltrating lymphocytes at the
interface. The isolated lymphocytes were washed twice with HBSS-2 prior to staining.
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Tumor Flow Cytometry

Cell staining for flow cytometry was performed on ice and protected from light.
Cells isolated from tissue were incubated with Fc block (TruStain fcX, anti-mouse
CD16/32 Ab, Biolegend) to prevent nonspecific binding. The relevant surface
antibodies were diluted in Fc block and allowed to incubate for 20 minutes. Cells
were subsequently washed and fixed (Fixation Buffer or Fix/Perm, for
intracellular staining, BD Biosciences). For intracellular staining, relevant
antibodies, diluted in Perm/Wash Buffer (BD Biosciences), were applied to cells
and allowed to incubate for 30 minutes. After staining steps, cells were washed
once with FACS buffer (25mM HEPES, 2% FBS, 10mM EDTA, 0.1% sodium azide
in PBS) and filtered through 70um mesh prior to flow cytometry analysis. The
stained cells were run on a LSRII Flow Cytometer using BD FACSDiva software
(BD Biosciences). Data were processed on FlowJo software (Treestar). Forward
and side scatter were used to exclude dead cells and doublets.

Cell culture

The PANC1, BxPC, MiaPaca2 cell-lines were purchased from ATCC. 293T,
MiaPaca2, KPC (B6/S129), Lx-2 and PANC1 cells were cultured in DMEM media
(Life Technologies) supplemented with 10% FBS (Sigma-Aldrich), sodium
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pyruvate (Life Technologies), L-glutamine (Life Technologies), amphotericin B
(Lonza) and penicillin-streptomycin (Life Technologies). BxPC cells were
cultured in RPMI media (Life Technologies) supplemented with 10% FBS (SigmaAldrich), sodium pyruvate (Life Technologies), L-glutamine (Life Technologies),
amphotericin B (Lonza) and penicillin-streptomycin (Life Technologies). For
hypoxic cell cultures, cells were cultured in 0.5 % oxygen within a cell culture
chamber with adjustable oxygen setting (Baker Ruskinn Invivo2 400
workstation).

Transcriptomic profiling

Total RNA was extracted from PANC1, PANC1-LM3, KPC, KPC-LM2 cells using
a Total RNA Purification Kit (Norgen Biotek) with on-column RNAse free
DNAse (Norgen Biotek) treatment. The total RNA extracted was then processed
using the Ribo-Zero Gold rRNA Removal Kit (Illumina) following the
manufacturer’s protocol. The resulting RNA was prepared into a sequencing
library using ScriptSeq™ v2 RNA-Seq Library Preparation Kit (Illumina)
following the manufacturer’s protocol. The resulting library was analyzed using
Tapestation to check for the RNA quality before the library was sequenced using
Illumina HiSeq 2500 by The Rockefeller University genomics core facility. Reads
were first trimmed to remove linker sequences and low-quality bases using
Cutadapt. TopHat2 was then used to map the reads to the human (RefSeq
!36

transcriptome index hg19) or mouse transcriptome (RefSeq transcriptome index
mm10). Cufflinks was then used to estimate RPKM (reads per kilobase per
million mapped reads) values and compare parental and highly metastatic sublines samples.

Generation of lentivirus, retrovirus, knock-down, inducible knock-down, and
over-expressing cells.

For generation of lentivirus delivering shRNAs or over-expression vectors, 293T
cells were seeded onto 10cm plates such that cell confluency would be
approximately 70% the next day. 3#g each of pRSV-Rev, pCMV-VSVG-G and
pCgpV packaging vectors (Cell Biolabs) were co-transfected with 9#g the
appropriate pLKO-shRNA, tet-on pLKO-shRNA, or pLenti-overexpression
plasmids using 37.5 #l of Lipofectamine 2000 in antibiotic-free DMEM media.
After 16hrs, the media was replaced with fresh antibiotic-free media. After 24hrs,
virus-containing supernatant was collected and filtered through a 0.45#m filter.
For transduction of cells, 2mL of the appropriate virus was used to transduce 1 x
5
10 cells in the presence of 8#g/mL polybrene. Media was replaced 24hrs later.

48 hrs after transduction, antibiotic selection was performed with either
blasticidin (10- 15#g/mL) or puromycin (2-4#g/mL) for 2-7 days alongside a
population of untransduced control cells. Selection is deemed completed after
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un-transduced control cells were killed by antibiotic selection. After selection,
cells were allowed to recover in selective antibiotic free media for 72hrs and
tested for over- expression or knockdown of gene of interest by qRT-PCR and
Western- blot where applicable. A list of the shRNA sequence is shown in Table
2.1. GeneBlock sequence of the C-terminus flag tagged NPTX1 is shown below,
and cloning primers are shown in Table 2.2.

PCR for cloning or genomic DNA amplification

PCR for cloning or genomic DNA amplification was performed using Phusion
enzyme (NEB) according to manufacturer’s protocol. Generally 200 to 400ng of
starting template were used. PCR products were visualized using gel
electrophoresis, excised and purified using Qiagen gel-extraction kit. Restriction
digest was performed NEB restriction enzymes, at 37 degree Celsius for 6hrs and
ligation into appropriate vector performed using NEB T4 ligase, at 16 degree
Celsius overnight.
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Table 2.1 shRNA sequences
Gene

shRNA

Sequence

NPTX1

1 CCGGCGACGCGCTTCATCTGCACTTCTCGAGA
AGTGCAGATGAAGCGCGTCGTTTTTG

NPTX1

3 CCGGCCCATGGAGATCCTCATCAATCTCGAGA
TTGATGAGGATCTCCATGGGTTTTTG

Nptx1

C

CCGGGAGACAAGTTTCAGCTGACATCTCGAG
ATGTCAGCTGAAACTTGTCTCTTTTTG

Nptx1

D

CCGGTGCGGACCAACTACATGTATGCTCGAG
CATACATGTAGTTGGTCCGCATTTTTG

Control

CCGGCAACAAGATGAAGAGCACCAACTCGA
GTTGGTGCTCTTCATCTTGTTGTTTTTG
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Sequence of gBlock NPTX1 with C-terminus flag tag
CGCATAGGATCCATGCCCGCTGGCAGAGCTGCGAGGACATGTGCGCTGCTCGCG
CTCTGCCTCCTCGGTGCGGGCGCCCAAGATTTTGGACCCACCAGATTCATCTGCA
CATCCGTGCCGGTTGACGCAGACATGTGCGCTGCCTCAGTGGCTGCAGGCGGCG
CTGAGGAGCTTAGATCTAGCGTACTTCAGCTCAGGGAGACAGTTCTGCAGCAGA
AAGAGACGATATTGTCACAAAAGGAGACCATTCGCGAGCTCACCGCTAAATTGG
GCCGGTGCGAATCTCAAAGCACCCTTGACCCCGGCGCTGGAGAGGCACGCGCA
GGGGGAGGCCGGAAACAGCCTGGCAGTGGCAAGAACACCATGGGGGACCTGTC
TCGGACGCCAGCTGCTGAAACCCTCAGTCAGCTGGGACAAACGCTGCAGAGTCT
TAAAACGAGGCTGGAAAATCTCGAACAATACTCCCGGCTTAACTCCTCCAGTCA
AACAAACTCCCTTAAGGATCTCCTGCAAAGCAAGATCGATGAACTGGAGAGACA
GGTGCTTAGTAGGGTCAATACACTCGAGGAGGGTAAAGGCGGCCCTAGAAACGA
TACAGAAGAAAGGGTGAAAATCGAAACTGCTCTGACAAGCCTTCACCAGAGGA
TATCAGAGCTGGAAAAGGGCCAGAAGGACAACAGGCCGGGAGACAAGTTCCAG
TTGACTTTCCCACTGAGGACCAACTACATGTACGCGAAAGTGAAGAAGTCCCTG
CCTGAAATGTACGCGTTTACTGTGTGTATGTGGCTCAAAAGCAGCGCTACTCCTG
GAGTGGGAACACCATTTTCTTACGCTGTTCCTGGCCAGGCAAATGAGTTGGTTCT
GATTGAATGGGGCAATAACCCCATGGAGATCCTGATAAACGATAAGGTGGCCAA
GTTGCCATTCGTGATCAATGACGGTAAGTGGCACCACATATGTGTCACATGGACC
ACAAGGGATGGCGTGTGGGAGGCCTACCAGGACGGGACCCAAGGGGGCTCCGG
GGAGAATTTGGCCCCTTACCACCCTATCAAACCCCAAGGTGTGCTCGTGCTGGGA
CAGGAGCAGGACACCTTGGGTGGAGGTTTTGACGCAACTCAAGCCTTCGTGGGG
GAACTGGCTCACTTCAACATCTGGGACCGCAAGCTGACCCCTGGAGAAGTCTAT
AATCTGGCCACGTGTTCTACAAAGGCTCTCAGTGGCAATGTTATTGCCTGGGCTG
AGTCACACATCGAGATCTATGGCGGCGCTACTAAGTGGACCTTCGAGGCC TGT
CGA CAA ATC AAC GAC TAC AAA GAC GAT GAC GAC AAG TGA

Table 2.2 Cloning primers
Cloning primer

Sequence

NPTX1 O/E Cflag F

CGCATAGGATCC ATG CCC GCT GGC AGA GCT
GCG AGG ACA TGT GCG CTG CT

NPTX1 O/E Cflag R

CGC ATA GTC GAC TCA CTT GTC GTC ATC GTC
TTT GTA GTC GTT GAT TTG TCG ACA
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DsiRNA mediated gene knockdown

TM

DsiRNA (IDT) was transfected into cells using lipofectamine 2000

for 6 hours.

Cells were used for hypoxia proliferation assay 72 hours post transfection.
DsiRNA design ID that were used are shown in Table 2.3.
Table 2.3 DsiRNA ID
Gene

DsiRNA ID

NPTX1

hs.Ri.NPTX1.13.1

NPTX1

hs.Ri.NPTX1.13.2

NPTX1

hs.Ri.NPTX1.13.3

EGR1

hs.Ri.EGR1.13.1

EGR1

hs.Ri.EGR1.13.2

HIF1a

hs.Ri.HIF1A.13.1

HIF1a

hs.Ri.HIF1A.13.2

Analysis of mRNA expression

Total RNA was extracted from the various cell lines using Total RNA Extraction
Kit (Norgen Biotek). For quantification of mRNA, 1#g of total RNA was reverse
transcribed using the cDNA First-Strand Synthesis Kit (18080-051, Invitrogen).
Approximately 50ng of the resulting cDNA was then mixed with SYBR green
PCR Master MIX (4309155, Applied Biosystems) and appropriate primers (Table
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2.4 and 2.5). Quantitative mRNA expression data was obtained using an ABI
Prism 7900HT Real-Time PCR System (Applied Biosystems). GAPDH was used
as an endogenous control for normalization.

Table 2.4 Human qRT-PCR primers
Gene

Forward primer

Reverse primer

GAPDH

AGCCACATCGCTCAGACAC

GCCCAATACGACCAAATCC

NPTX1

CCT GGA GAA CCT CGA GCA GAT CCT TGA GGC TGT TGG
TC

ACTA2

CGT GGC TAT TCC TTC GTT
ACT AC

EGR1

CTT CAA CCC TCA GGC GGA GGA AAA GCG GCC AGT
CA
ATA GGT

HIF1a

GAA AGC GCA AGT CTT CAA TGG GTA GGA GAT GGA GAT
AG
GC

CAG GCA ACT CGT AAC TCT
TCT C

Table 2.5 Mouse qRT-PCR primers

Gene

Forward primer

Reverse primer

Gapdh

AGGTCGGTGTGAACGGATTT GGGGTCGTTGATGGCAACA
G

Nptx1

CCA AGC TGC CGT TTG TAA
TC

GAT AGG GTG CCA AGT TCT
CTC

Acta2

CCG ATA GAA CAC GGC ATC
AT

CTC CAG AGT CCA GCA
CAA TAT
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Cell proliferation assays in hypoxia, anoxia, and normoxia

4
For in vitro cell proliferation assays in normoxia, 8 x 10 PANC1 LM3 or PANC1

cells were seeded onto 6-well plates (Falcon) in triplicates. Cells were kept in
culture for 6 days before collection through trypsin digestion and counted using
the Scepter™ 2.0 Handheld Automated Cell Counter (Millipore) or stained with
trypsin blue and counted using a hemocytometer. Experiments were repeated

for at least three times. For in vitro hypoxia proliferation assays, 8 x 10

4

PANC1

LM3 or PANC1 cells were seeded in 6-wells plate in triplicates and were cultured
in 0.5% oxygen (Baker Ruskinn Invivo2 400 workstation) in regular cell culture
media for 6 days before counting. Experiments were repeated at least two times.
Cell counts were normalized to that of control conditions. For in vitro anoxia
4
proliferation assays, 8 x 10 PANC1 LM3 or PANC1 cells were seeded in 6-wells

plate in triplicates and were cultured in anoxic condition using Bio-Bag™ (BD).
Cells were cultured for 3 days and were washed once with PBS before being
trypsinized for cell counting. Live and dead cells were counted after Trypan Blue
staining using a hemocytometer. Only cells cultured in the same Bio-Bag™ are
compared.
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Collection of cell culture supernatant for western blot

6
6 x 10 cells were seeded onto 15cm cell culture dishes. After allowing cells to

attach overnight, cells were washed gently three times with 15 mL PBS and
routine culture media was replaced with 15mL serum free media and cultured
for an additional 16 hrs. Supernatant was collected and filtered using 0.22 uL
filter. The filtered supernatant was then centrifuged for 800g for 10min to remove
debris. Subsequently, the supernatant was concentrated using a spin column
with 10kD cut-off filter to approximately 250uL prior to downstream
applications. To perform extracellular NPTX1 western blot, 750uL (or 3x volume
of the filtered supernatant concentrate) of ice-cold acetone was added to 250uL of
the concentrated supernatant and incubated in -20 degree celsius overnight. The
supernatant-acetone mixture was then centrifuged at maximum speed in a table
top centrifuge for 10 seconds under 4 degree celsius twice. The supernatant was
then aspirated carefully and the pellets were left to dry in a fume hood on ice.
After the remaining acetone evaporated, the pellets were resuspended in loading
buffer . The samples were then boiled at 95 degrees celsius for 5 minutes, and

!44

were span down at maximum speed for 5 minutes again at room temperature to
ensure there was not precipitate and the whole pellet was completely dissolved.

Western-Blot

Cell lysates or concentrated extracellular supernatant were prepared by either
lysing cells grown on 10cm plates in 1mL of RIPA buffer containing protease
inhibitors or the supernatant collection method described above. Lysate or the
supernatant concentrate were quantitated using Bio-Rad BCA kit. 40#g protein
from cell lysates were separated on a 4-12% SDS-PAGE and transferred to a
PVDF membrane. Membrane was blocked for 1hr in 5% milk in TBST (except for
FLAG antibody, blocking was performed in 5% BSA in TBST for 1hr). Antibodies
were incubated overnight in 5% BSA in TBST at 4 degrees with gentle rocking.
The NPTX1 antibody was purchased from Abcam (Cat. ab191201, 1:500 dilution).
(GAPDH antibody was purchased from Genetex (Cat. GTX627408, 1:5000
dilution). The FLAG antibody was purchased from Sigma (Cat. F3165, 1:1000
dilution). Horseradish peroxidase-conjugated secondary antibodies were
purchased from GE Health Sciences and used at a dilution of 1:2000, in 2.5% milk
in TBST for 1hr. In between antibody incubation, membranes were washed 3X in
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TBST, 5mins per wash. Chemiluminescent detection of proteins was performed
using Pierce ECL plus kit.

Histology

Livers were prepared by 48 hour fixation with 4% paraformaldehyde in 4C while
shaking. After fixation, the livers were embedded in paraffin. 5#m thick paraffin
sections were stained with primary antibodies shown in Table 2.6. Primary
antibodies were detected using various Alexa Flour dye-conjugated secondary
antibodies. Fluorescence was obtained using a Zeiss laser scanning confocal
microscope (LSM 510).

Subcutaneous tumours were excised and submerged into 4% paraformaldehyde
for 24 hours. The fixed tissue was embedded in paraffin and sectioned in 5 #m
thick slices. Sections were stained with primary antibodies shown in Table 2.6.
Primary antibodies were detected using various Alexa Flour dye-conjugated
secondary antibodies. Fluorescence was obtained using a Zeiss laser scanning
confocal microscope (LSM 510).

An intraperitoneal injection of 60mg/kg pimonidazole HCl/Hypoxyprobe (NPI
Inc) was infused into each mice. 90 min after, the mice were anaesthetized and
the livers were extracted following protocols described above. The livers were
submerged in 4% paraformaldehyde for 24 hours at 4 degree Celsius shaking.
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The livers were then embedded in OCT and frozen on dry ice. 10 #m section was
cut and stained with pimonidazole antibody conjugated to Dylight™549. The
sections were then imaged using a Zeiss laser scanning confocal microscope
(LSM 510).

Table 2.6 Antibodies used in histology
Gene

Company

Clone

Host

Dilution

Vimentin

Vector Lab

VP-V684

Mouse

1:50

Ki-67

Abcam

ab 15580

Rabbit

1:200

Endomucin

Santa Cruz

V. 7C7

Rat

1:200

F4/80

Biorad

MCA497

Rat

1:100

aSMA

Millipore

ASM-1

Mouse

1:1000

aSMA

Abcam

E184

Rabbit

1:500

Mouse plasma NPTX1 ELISA

NPTX1 levels in mouse plasma of the xenograft pancreatic cancer model were
quantified using the human NPTX1 ELISA kit (Biomatik, EKU06234) following
the manufacture’s protocol.
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Analysis of Genomic Copy Number

Total genomic DNA was extracted and purified from cell populations using the
DNeasy kit (Qiagen). For DNA content normalization, GAPDH was used as
endogenous control. Primers used in the qRT-PCR for genomic copy number is
shown in Table 2.7 .

Table 2.7 Genomic copy number qRT-PCT primers
Gene

Forward primer

Reverse primer

NPTX1

AAGACAACCGCCCTGGA

CACTCAATGAGGACCAGCTC

GAPDH AGCCACA TCGCTCAGACAC
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GCCCAATACGACCAAATCC

Patient derived pancreatic cancer cell lines, tumor sample RNA and normal
pancreatic RNA

All patient derived pancreatic cancer cell lines and tumor sample RNA were
generously shared by Dr. Christine Iacobuzio-Donahue from Memorial-Sloan
Kettering Cancer Center. Normal pancreatic RNA was purchased from OriGene
and Thermo Fisher Scientific.
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Chapter III: The Systematic Discovery of Metastatic Regulators in
Pancreatic Cancer
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Establishment of xenograft and syngeneic mouse models to study liver
metastatic colonization of pancreatic cancer cells
As a first step to discover novel metastatic regulators in pancreatic cancer, I
performed in vivo selection to develop both syngeneic and xenograft mouse
models comprised of poorly and highly metastatic pancreatic cancer cells. In vivo
selection has already been successfully applied to study metastasis in multiple
cancer models and identified important genetic programs that regulate various
steps of the metastatic cascade (Loo et al., 2015; Pencheva et al., 2012; Tavazoie et
al., 2008). This approach takes advantage of the heterogeneity of cancer cell
populations, where small subpopulation of cells express enhanced metastatic
capability. This subpopulation of cells possess survival advantages compared to
the parental cells in vivo, and by injecting those parental cells into mice and
isolating metastatic nodules and repeating the same process multiple times, this
subpopulation of highly metastatic cells can be selected or isolated from the more
heterogeneous parental population. Once the highly metastatic cells are selected,
they can be compared at the transcriptomic level to the parental population to
uncover the molecular signatures these highly metastatic cells utilize to
metastasize. The highly metastatic subpopulation differentially express genetic
programs that are crucial to cellular functions important to specific steps in the
metastatic cascade. Based on this hypothesis, many prior studies have identified
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molecular programs that functionally regulate metastasis by comparing the
transcriptomic profiles of the in vivo selected, highly metastatic derivatives to the
parental populations.

Most of the prior studies have performed in vivo selection using an
immunocompromised mouse model in order to allow metastatic growth of
human derived cancer cells. With the advancements in the murine pancreatic
cancer models, it could also be possible to in vivo select a murine cancer models
derived cell line under a syngeneic and immunocompetent background. This
syngeneic model would take account into the immune regulation of metastasis
when comparing the gene expression of highly metastatic cells and the lowly
metastatic parental populations.

In order to identify genetic regulators of metastasis in pancreatic cancer, I chose
to use the PANC1 human pancreatic cancer cell line because it is a widely used
cell line available through ATCC and it contains the most prevalent mutations in
KRAS and TP53. I used PANC1 line to perform in vivo selection using the
immunocompromised Nod Scid Gamma mice. Nod Scid Gamma mice lack an
adaptive immune system and nature killer cells, and have defective macrophages
and dendritic cells to allow xenograft of human derived cell lines.

To

complement this approach I took advantage of a murine cancer cell line derived
!52

from the mouse pancreatic cancer model: K-rasLSL.G12D/+; p53R172H/+;
PdxCre (KPC mouse) (Torres et al., 2013) and performed in vivo selection under a
syngeneic and immunocompetent context.

Since the majority of pancreatic cancer patients present to the clinic with seeded
macro-metastases in distal organs, I was interested in identifying genetic
programs that regulate the later steps of metastatic progression, especially distal
organ metastatic colonization. The most common site of distal metastasis in
pancreatic cancer is the liver. I performed in vivo selection to isolate a
subpopulation of cancer cells that could better survive and colonize the liver. To
perform this in vivo selection, I directly injected PANC1 and KPC cells
intrahepatically to specifically select for a subpopulation of cancer cells with
enhanced liver metastatic colonization capabilities and followed the injection by
surgical resection of liver colonies, dissociation of cells, and subsequently reinjected the isolated cancer cells back into the liver (Figure 3.1).
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repeat 1-2 more times
Expand
in culture

2-5 weeks
Intrahepatic
injection

Tumor growth
and extraction

Figure 3.1 Schematics of the strategy to derive highly-metastatic pancreatic
cancer cells using in vivo selection.
5
5 x 10 luciferase labeled PANC1 were intrahepatically injected into the
5
immunodeficient Nod Scid Gamma mice with matrigel, and 5 x 10 luciferase
labeled KPC cells were intrahepatically injected into the syngeneic and
immunocompetent B6129SF1/J mice with matrigel. Tumor cells were
monitored using bioluminescence imaging and allowed to grow for 2-5 weeks
before tumor nodules were extracted and expanded in vitro.
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After repeating this selection procedure two to three times, I isolated several
second or third generation liver colonizing cells, KPC LM2 and PANC1 LM3 sublines. The independently derived KPC LM2 and PANC1 LM3 (Figure 3.2) sublines were passaged in vitro and their liver metastatic capabilities were compared
by splenic injection of equal number of cells into the portal circulation. In both
the xenograft and murine syngeneic systems, the in vivo selected PANC1 LM3
and KPC LM2 cells displayed significantly enhanced metastatic capabilities (>30
fold by third week in PANC1 LM3, and >100 folds by second week in KPC LM2,
Figure 3.3 and 3.4)—arguing for successful achievement of in vivo selection for
enhanced metastatic fitness in the liver.

PANC1

KPC

LM1-a

LM2-a

LM1-b

LM2-b

LM1-a
LM1-b
LM1-c

LM3-a
LM3-b
LM3-c
LM2-a
LM2-b
LM2-c

Non-metastatic
parental

Highly metastatic
derivatives

Figure 3.2 Lineages of the independently in vivo selected PANC1 and KPC
cells. Multiple independently derived KPC LM2 or PANC1 LM3 cells were
established using in vivo selection.
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Figure 3.3 In vivo selected PANC1 LM3 cells colonize the liver more
efficiently compared to the parental PANC1 cells. Highly metastatic PANC1
LM3 cells could colonize the liver 30 folds more efficiently compared to the
5
PANC1 parental cells by day 19 after splenic injection of 5 x 10 cells into the
NSG mice. ***P<0.001 by 2-tail student’s t-test.
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Figure 3.4 In vivo selected KPC LM2 cells colonize the liver more efficiently
compared to the parental KPC cells. Highly metastatic KPC LM2 cells could
colonize the liver 500 folds more efficiently compared to the KPC parental cells by
5
day 12 after splenic injection of 3 x 10 cells into the B6129SF1/J mice. ***P<0.001
by 2-tail student’s t-test.
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While the parental PANC1 cells stalled and stopped further metastatic
colonization of the liver after two weeks of initial growth, the highly metastatic
PANC1 LM3 cells continued to grow rapidly until the liver was completely
colonized and increased several fold larger in size (Figure 3.5). The enhanced
liver metastatic colonization capability of the PANC1 LM3 cells were retained
after more than 25 passages in vitro (Figure 3.6), demonstrating that the selected
subpopulation of highly metastatic cells expressed metastasis promoting
molecular programs that were inheritable.

Liver metastasis assay

A.

Liver photon flux ratio
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B.

PANC1

***

PANC1 LM3-a
PANC1 LM3-b
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10
Day

15
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Figure 3.5 Liver metastatic colonization growth curves comparing parental
PANC1 to the highly metastatic PANC1 LM3 sub-lines. The highly metastatic
PNAC1 LM3 cells continued to colonize the liver while the parental PANC1
cells stalled in growth after the second week. Metastatic growth was monitored
using bioluminescence imaging. ***P<0.001 by 2-tail student’s t-test.
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Figure 3.6 The highly metastatic PANC1 LM3 sub-lines retain the increased
liver metastatic colonization capabilities after 25 passages in vitro. Two
independently derived PANC1 LM3 cell lines were passaged in vitro for more
than 25 passages and their liver metastatic colonization capabilities were
compared to the parental PANC1 cells. Passaged PANC1 LM3 cells retained
their highly metastatic capabilities. ***P<0.001 by 2-tail student’s t-test.
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Metastatic colonization, the formation of micro-metastases and subsequently
macro-metastases, is a significant rate-limiting step during metastatic growth.
The highly metastatic PANC1 LM3 cells were selected by their abilities to survive
and grow in the liver microenvironment and when implanted into the pancreas
of the Nod Scid Gamma mice, PANC1 LM3 cells were able to metastasize to
distal organs such as the liver while the parental cells were unable to metastasize
and mostly stayed locally in the pancreas (Figure 3.7). The highly metastatic KPC
LM2 cells displayed similar traits (Figure 3.8).

To investigate if the in vivo selected PANC1 LM3 cells displayed organ specific
tropism and could metastasize to the lung, I injected the PANC1 and PANC1
LM3 cells into the venous circulation. After the PANC1 LM3 cells were injected
into the venous circulation via tail vein, five out of five mice developed widelyspread metastases in distal organs including the liver, lung, peritoneum and the
adrenal glands while only two out of the five mice injected with parental cells
exhibited

limited

metastatic

growth

(Figure

3.9).

When

implanted

subcutaneously, the highly metastatic KPC LM2 cells also grew significantly
faster compared to the parental cells (Figure 3.10). These findings reveal that the
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in vivo selected PANC1 LM3 and KPC LM2 cells were highly metastatic to

Liver photon flux ratio

multiple distal organs as well as having enhanced tumor growth capabilities.

10000

LM3

Primary tumor

Liver metastasis

Liver

PANC1

Primary tumor

Liver metastasis

Liver

***

1000
100
10
1
0.1

PANC1 PANC1 LM3

Figure 3.7 The highly metastatic PANC1 LM3 cells colonize the liver more
5
efficiently from the pancreas compared to PANC1 cells. 5x 10 of PANC1 or
PANC1 LM3 cells were injected into the pancreas of NSG mice with materiel.
Mice were imaged and sacrificed 6 weeks post injection. *** p<0.001 using 2
sided student’s t-test.
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Figure 3.8 The highly metastatic KPC LM2 cells colonize the liver more
5
efficiently from the pancreas compared to KPC cells. 3x 10 of KPC or KPC
LM2 cells were injected into the pancreas of B6129SF1/J mice with materiel, and
the mice were imaged and sacrificed 4 weeks post injection. *p<0.05 using 2
sided student’s t-test.
LM3-b

PANC1

Figure 3.9 PANC1 LM3 cells have enhanced systemic metastatic capabilities
4
compared to the parental PANC1 cells. 2x 10 PANC1 or PANC1 LM3 cells were
injected via tail vein of the NSG mice. Mice were imaged at day 53.
!61

Subcutaneous growth assay

D.

Tumor volume in mm^2

800

**

600

400

200

0

KPC

KPC LM2

Figure 3.10 KPC LM2 cells have enhanced tumor growth capabilities
6
compared to the parental KPC cells. 1x 10 KPC and KPC LM2 cells were
injected subcutaneously and the tumor size was measured at day 28. ** p<0.01
using 2 sided student’s t-test.
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Highly metastatic pancreatic cancer cells express higher levels of NPTX1 than
their respective parental populations.
We next sought to identify the molecular programs that led to the enhanced
metastatic and tumor growth capabilities of the PANC1 LM3 and KPC LM2 cells.
In vitro, both the PANC1 LM3 and KPC LM2 cells grew slower compared to their
respective parental cell lines (Figure 3.11). Thus, in vivo selection did not select for
faster growing cells and the enhanced metastatic and orthotopic tumor growth
capabilities in vivo were not due to intrinsically faster growing cells. The in vivo
selected PANC1 LM3 and KPC LM2 cells were specific subpopulations that could
survive and proliferate at higher efficiency in the tumor microenvironment in
vivo. Since the KPC LM2 cells were in vivo selected under an immunocompetent
background, we sought to characterize the immune modulating capabilities of
the highly metastatic KPC LM2 cells by profiling the infiltrating immune cells in
the liver metastases. The KPC LM2 liver metastases exhibited multiple
characteristics of tumor immunosuppression including decreased CD8+ T cells,
increased myeloid derived suppressor cells, and decreased B-cells (Figure 3.12).
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Figure 3.11 The highly metastatic PANC1 LM3 and KPC LM2 cells proliferate
at a slower rate in vitro compared to the parental PANC1 and KPC cells.
PANC1 LM3 cells proliferated at a slower rate compared to the parental PANC1
cells in vitro under standard cell culture condition. In vivo selected KPC LM2
cells also proliferated at a slower rate in vitro compared to the parental KPC
cells population. * p<0.05 using 2 sided student’s t-test.
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Figure 3.12 The highly metastatic KPC LM2 cells are associated with a
immunosuppressive microenvironment in liver metastatic nodules. 5x 10

5

KPC or KPC LM2 cells were injected into the portal circulation. At Day 10, the
murine livers with metastatic
growth
were
harvested
and the immune cell
RNAseq data
pathway
analysis
visualization
infiltrates of the liver metastases were profiled using flow cytometry. ** p<0.01
using 2 sided student’s t-test. *** p<0.001 using 2 sided student’s t-test.

Supplementary Figure 2
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To better understand the gene expression changes in the highly metastatic
PANC1 LM3 and KPC LM2 cells, I performed transcriptomic profiling
comparing the lowly metastatic parental cells, PANC1 and KPC, with three
independently derived, highly metastatic PANC1 LM3 or KPC LM2 sub-lines to
identify metastasis-regulating molecular programs. Compared to the parental
PANC1 cells, the highly metastatic PANC1 LM3 cells expressed 154 significantly
up-regulated genes (adjusted p-value <0.05) and 121 down-regulated genes. The
highly metastatic KPC LM2 cells expressed 205 significantly up-regulated genes
and 67 down-regulated genes (Figure 3.13) compared to their respective lowlymetastatic parental KPC cells.
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Figure 3.13 Transcriptomic profiling revealed 12 commonly de-regulated
genes in both PANC1 LM3 and KPC LM2 cells compared to their respective
parental PANC1 and KPC cells. Transcriptomic profiling was performed on
three independently in vivo selected sub-lines in each system. 10 genes were
commonly up-regulated in both PANC1 LM3 and KPC LM2 compared to the
parental cells, and 2 genes were commonly down-regulated in both systems.

!67

I then overlapped the significantly up-regulated and down-regulated genes to
identify commonly de-regulated genes in both the xenograft and syngeneic
systems. I found 10 commonly up-regulated genes and 2 commonly downregulated genes. When these 12 commonly de-regulated genes were ranked by
their average p-values among the xenograft and syngeneic models, the most
significantly de-regulated gene identified was Neuronal Pentraxin 1 (NPTX1,
Table 3.1). NPTX1 was expressed 7.45 folds higher on average in multiple
independently selected PANC1 LM3 derivatives compared to the parental cells,
and 7.57 fold higher on average in the multiple independently selected KPC LM2
derivatives (Table 3.1 and Figure 3.14).

NPTX1 is a secreted glycoprotein that is involved in synaptic plasticity and
apoptosis upon oxygen and glucose deprivation in the nervous system
(Schlimgen et al., 1995; Sia et al., 2007; Thatipamula and Hossain, 2014). It was
previously described as exclusively expressed in the nervous system, and under
healthy condition, NPTX1 was not expressed in the pancreas (Atlas, 2017). The
function of NPTX1 outside of the nervous system has been poorly characterized,
and the functional role of NPTX1 in cancer otherwise remains unknown.
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Table 3.1 Commonly de-regulated genes ranked by average P-value. 12
genes were commonly de-regulated between PANC1 LM3 and KPC LM2
compared to parental cells. Genes were ranked by average P-value.

Gene ID

PANC1 LM3

KPC LM2

(Log2 fold change) (Log2 fold change)

NPTX1
COL6A1
DSC2
RHOBTB3
COL5A1
COL6A2
NES
CLDN4
DSG2
NAV3
GLDC

neuronal pentraxin I
collagen 6A1
desmocollin 2
rho-related BTB domain containing 3
collagen 5A1
collagen 6A2
nestin
claudin 4
desmoglein 2
neuron navigator 3
glycine dehydrogenase
calcium channel, voltage-dependent,
CACNA2D1 alpha 2/delta subunit 1
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Average p-value

2.91439
5.4328
1.80064
-1.14907
1.37378
5.96115
1.42819
-1.92114
1.25029
2.89781
1.30227

2.92003
2.13477
3.41506
-1.54822
2.04274
1.61443
1.32981
-2.05676
1.43351
1.53956
1.89255

3.18E-14
5.01E-11
3.59E-08
1.14E-07
4.25E-07
9.48E-07
3.44E-06
1.41E-05
1.55E-05
9.34E-05
2.42E-04

1.28834

1.20153

2.69E-04
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Figure 3.14 Volcano plot of transcriptomic profiling comparing the highly
metastatic PANC1 LM3 and KPC LM2 cells to their parental PANC1 and KPC
cells. The 12 commonly de-regulated genes are highlighted in black, while
NPTX1 and Nptx1 are highlighted in red.
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NPTX1 promotes human and murine pancreatic cancer metastatic and tumor
progression.
To confirm the transcriptomic profiling findings, I validated the expression levels
of human NPTX1 and murine Nptx1 in the highly metastatic sub-lines compared
to the respective poorly metastatic parental cells. By qRT-PCR, I confirmed a
consistent up-regulation of NPTX1 in the PANC1 LM3 and KPC LM2 sub-lines
compared to their respective parental cells (Figure 3.15). To further investigate
the functional role of NPTX1 in pancreatic cancer, I stably knocked down NPTX1
in PANC1 LM3 cells with two independent shRNA’s delivered through a
lentiviral mediated system and performed liver metastatic colonization assays
(Figure 3.16). Suppression of NPTX1 in PANC1 LM3 cells led to robust reduction
in liver metastatic colonization (>40 folds reduction by fourth week of liver
metastasis assay) and knockdown of Nptx1 using two independent shRNA’s in
KPC cells also led to significantly reduced liver metastatic colonization (Figure
3.17 and 3.18). Knockdown of NPTX1 with two independent shRNAs in a second
human pancreatic cancer cell line, MiaPaCa2 (P53 and KRAS mutants), also
caused significantly reduced liver metastatic colonization (Figure 3.19).
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Figure 3.15 Highly metastatic PANC1 LM3 cells express NPTX1 at a higher
level compared to the lowly-metastatic parental PANC1 cells. Highly
metastatic KPC LM2 cells expressed Nptx1 at a higher level compared to the
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Figure 3.16 Depletion of NPTX1 in the PANC1 LM3 cells using a lentiviral
mediated shRNA system yielded >50% knockdown with two independent
shRNA hairpins. Depletion of Nptx1 in the KPC cells using a lentiviral
mediated shRNA system also yielded >50% knockdown at the mRNA level.
***p<0.001 using 2 sided student’s t-test.
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Figure 3.17 Endogenous NPTX1 promotes liver metastatic colonization
by PANC1 LM3 cells. Depletion of NPTX1 using a lentiviral mediated
shRNA system with two independent shRNA’s in the highly metastatic
PANC1 LM3 cells led to significant reduction in liver metastatic
colonization in vivo using the NSG xenograft mouse model. ***p<0.001
using 1-sided student’s t-test. **p<0.01 using 1-sided student’s t-test.
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Figure 3.18 Endogenous Nptx1 promotes liver metastatic colonization by KPC
cells. Depletion of Nptx1 using a lentiviral mediated shRNA system in the KPC
cells led to significant reduction in liver metastasis in vivo using a
immunocompetent, syngeneic mouse model. **p<0.01 using 1-sided student’s ttest.
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Figure 3.19 Endogenous NPTX1 promotes liver metastatic colonization by
MiaPaCa cells. Depletion of NPTX1 using a lentiviral mediated shRNA
system with two independent shRNA in the MiaPaCa cell line led to
significant reduction in liver metastatic colonization in vivo using the NSG
xenograft mouse model. ***p<0.001 using 1-sided student’s t-test. *p<0.05
using 1-sided student’s t-test.
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The highly metastatic PANC1 LM3 derivatives not only had enhanced abilities to
metastasize to distal organs, but also enhanced orthotopic tumor growth
capabilities. NPTX1 knockdown in PANC1 LM3 cells also led to a reduction in
orthotopic tumor growth (Figure 3.20), indicating that NPTX1 promoted growth
in orthotopic tumors as well as metastatic sites. Additionally, orthotopic
implantation of NPTX1 depleted PANC1 LM3 cells significantly decreased liver
metastatic colonization (Figure 3.21), suggesting that suppression of NPTX1
expression was sufficient to inhibit distal organ metastasis.
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Figure 3.20 Endogenous NPTX1 promotes orthotopic tumor growth by
PANC1 LM3 cells. Depletion of NPTX1 using a lentiviral mediated shRNA
system in the highly metastatic PANC1 LM3 cells led to significant
reduction in orthotopic tumor growth in vivo using the NSG xenograft
mouse model. *p<0.05 using 2-sided student’s t-test.
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Figure 3.21 Endogenous NPTX1 promotes distal organ metastasis from
the pancreas in PANC1 LM3 cells. Depletion of NPTX1 in PANC1 LM3
5
cells inhibited metastasis from the pancreas. 5x 10 PANC1 LM3 control or
NPTX1 knockdown cells were injected into the pancreas with matrigel.
Mice were imaged and sacrificed at week 5 after the injection. *p<0.05
using 2-sided student’s t-test.
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The highly metastatic PANC1 LM3 sub-lines differed from their PANC1 parental
cells most significantly after the initial metastatic seeding, especially during the
third week of growth in the liver as analyzed by bioluminescence imaging
during metastatic colonization assays (Figure 3.5). Based on this observation, I
investigated if NPTX1 promoted the growth of existing metastases by temporally
suppressing NPTX1 expression after cancer cells were allowed to initially
colonize the liver for several days. I generated a PANC1 LM3 cell line stably
transduced with lentriviral particles carrying a doxycycline (DOX)-inducible
shRNA targeting NPTX1. In the presence of DOX, NPTX1 expression was
decreased, thus allowing us to observe the effect of down-reagulating NPTX1 in
vivo post-colonization. We performed a metastatic colonization assay using NSG
mice and assessed liver metastatic growth by bioluminescence imaging. Regular
diet or diet containing DOX was given to the mice injected with PANC1 LM3
DOX-inducible NPTX1 knockdown cells 7 or 14 days after the injection (Figure
3.22 and 3.23 respectively). In both cases, suppressed metastatic progression was
observed indicating that even after the initial establishment of macro-metastases,
NPTX1 promotes distal organ metastatic outgrowth.
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Figure 3.22 Temporal suppression of NPTX1 7 days post metastatic seeding
decreases liver metastatic colonization. PANC1 LM3 cells were stably
transduced with a doxycycline inducible shRNA against NPTX1. On day 0, 5x
5

10

PANC1 LM3 cells with the dox-inducible shNPTX1 construct were

injected into the portal circulation of 10 NSG mice. On day 7, each mice was
randomly assigned into either the regular diet or doxycycline diet group.
Liver metastatic colonization was monitored using bioluminescent imaging
and mice were sacrificed at day 39. ***p<0.001 using 2-sided student’s t-test.
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Figure 3.23 Temporal suppression of NPTX1 14 days post metastatic
seeding decreases liver metastatic colonization. PANC1 LM3 cells were
stably transduced with a doxycycline inducible shRNA against NPTX1. On
5
day 0, 5x 10 PANC1 LM3 cells with the doxycycline inducible shNPTX1
construct were injected into the portal circulation of 10 NSG mice. On day
14, each mice was randomly assigned into either the regular diet or
doxycycline diet group. Liver metastatic growth was monitored using
bioluminescent imaging and mice were sacrificed at week 5. *p<0.05 using
2-sided student’s t-test.
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I concluded that NPTX1 was functionally necessary to promote both orthotopic
tumor growth and progression of distal liver metastatic colonization. We next
asked if NPTX1 over-expression was sufficient to enhance metastatic and
orthotopic tumor growth by poorly metastatic cells. I generated parental PANC1
cells stably over-expressing NPTX1 protein or GFP control using a lentiviral
mediated delivery system. PANC1 cells over-expressing NPTX1 colonized the
liver at the same rate as PANC1 cells over-expressing GFP (Figure 3.24) in vivo.
The pentraxin family proteins are known to form pentamers and higher order
oligomers (Xu et al., 2003). The CMV promoter used to drive the expression of
NPTX1 in PANC1 cells resulted in more than 100-fold increase in NPTX1
expression by mRNA and protein, and this high level of protein expression may
inhibit the correct formation of NPTX1 oligomers. Consistent with this
hypothesis, in the highly metastatic PANC1 LM3 cells with suppressed NPTX1
expression, over-expression of NPTX1 protein led to further decrease in liver
metastasis compared to over-expression of GFP protein (Figure 3.25).
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Figure 3.24 Over-expression of NPTX1 in PANC1 cells does not alter liver
5
metastatic capability of cancer cells. 5x 10 PANC1 cells transduced with a
CMV driven NPTX1 or GFP expression construct were injected into the portal
circulation of NSG mice via the spleen. Mice were imaged and sacrificed at
week 5.

!82

Liver metastasis assay

D.

Liver photon flux ratio

100000

PANC1 LM3 PANC1 LM3 PANC1 LM3
shCTRL
shNPTX1
shNPTX1
GFP OE
GFP OE
NPXT1 OE

**

*

10000

1000

shCTRL shNPTX1 shNPTX1
GFP OE GFP OE NPTX1 OE

PANC1 LM3

Figure 3.25 Over-expression of NPTX1 in PANC1 LM3 cells with NPTX1
knockdown lead to further suppression of liver metastatic colonization. 5x
5
10 cancer cells were injected into the portal circulations via the spleen. Mice
were imaged and sacrificed at week 6. **p<0.01 using 2-sides student’s t test.
*p<0.05 using 2-sided student’s t-test.
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NPTX1 is secreted by pancreatic cancer cells and is regulated in part by
epigenetic mechanism(s) and the EGR1 transcription factor
NPTX1 contains a signal peptide and is known to be secreted by neurons (Sia et
al., 2007). Because NPTX1 expression by pancreatic cancer cells was not
previously described, I examined if the pancreatic cancer cells also secreted
NPTX1 into the extracellular space. Consistent with the enhanced expression
observed at the mRNA level, I was able to detect higher levels of NPTX1 proteins
by western blot in the extracellular media of highly metastatic PANC1 LM3 cells
compared to the poorly metastatic PANC1 cells (Figure 3.26). In neurons, NPTX1
forms high molecular weight oligomers (Xu et al., 2003). I over-expressed NPTX1
in the PANC1 LM3 cells using a CMV promoter and found that NPTX1 was
capable of forming oligomers of various molecular weights (Figure 3.27).
Endogenously, the highly metastatic PANC1 LM3 cells secreted high MW
oligomers of NPTX1 at a higher levels compared to the parental PANC1 cells
(Figure 3.28).
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Figure 3.26 The highly metastatic PANC1 LM3 cells secret NPTX1 into the
extracellular space at higher quantity compared to the lowly metastatic
PANC1 cells. Top panel: NPTX1 western blot of PANC1 and PANC1 LM3
extracellular medium. Bottom panel: total secreted protein in the extracellular
medium stained by Ponceau Red.
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We next investigated the mechanism of NPTX1’s expression in highly metastatic
pancreatic cancer cells. A technician in the laboratory, Logan Mandez
characterized the genomic copy number of NPTX1 in PANC1 compared to
PANC1 LM3 cells by qRT-PCR. Using this technique, we found that the NPTX1
genomic copy number was unchanged, indicating that gene amplification was
unlikely to be the cause of the higher expression levels in the highly metastatic
PANC1 LM3 sub-lines (Figure 3.29). We then sought to test the potential role of
promoter methylation silencing of NTPX1 in pancreatic cells that could be lost
during metastatic progression. To test this hypothesis, I treated the parental
PANC1 cells in vivo with the DNA-methylase inhibitor 5-Azacytidine for 5 days.
This 5-Aza treatment resulted in a 2.2-fold increase in NPTX1 expression in
PANC1 cells as measured by qRT-PCR (Figure 3.30), suggesting that derepression of promoter methylation of the NPTX1 gene could be one mechanism
to enhance expression levels in the highly metastatic cancer cells. These results
are consistent with the literature where it has been proposed that epigenetic
modifications affects pancreatic cancer progression (McDonald et al., 2017) as
well as many other type of cancers (Esteller, 2008).
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Figure 3.29 Genomic copy number of NPTX1 in 293, PANC1 and multiple
sub-lines of the PANC1 LM3 cells measured by qRT-PCR. Genomic copy
number was unchanged among PANC1 and the highly metastatic sub-lines.
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Figure 3.30 5-Azacytidine, a DNA methylase inhibitor, treated PANC1 cells
up-regulate NPTX1 expression. PANC1 cells were treated with DMSO or 5Aza for 5 days. NPTX1 expression level was measured using qRT-PCR.
**p<0.01 using 2-sides student’s t test.
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I next searched for potential transcription factors with binding sites in the
promoter region of NPTX1. If my hypothesis was correct and demethylation of
the NPTX1 promoter was enough to enhance the expression of this gene then the
transcription factor(s) responsible for the transcription of NPTX1 must be present
already in the parental cell population. I searched for potential transcription
factors with binding site in the promoter region of NPTX1. Using the UCSCS
genome browser (https://genome.ucsc.edu) that contained information from
Encyclopedia of DNA Elements (ENCODE) with experimental chromatin
immunoprecipitation sequencing data obtained from multiple transcription
factors, I identified a number of candidates that could potentially activate the
transcription of NPTX1 (Figure 3.31).

Figure 3.31. Transcription factor binding sites in NPTX1 promoter. TF binding
sites from experimental chromatin immunoprecipitation sequencing data
archived in the Encyclopedia of DNA Elements (ENCODE) project in UCSC
genome browser.
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Among those candidates, EGR1 was shown previously to affect the expression of
multiple target genes including NPTX1 (Zhang et al., 2014). To test the role of
EGR1 in NPTX1 expression I transiently depleted EGR1 using two independent
siRNAs. EGR1 down-regulation led to reduced expression of NPTX1, suggesting
that NPTX1 expression in the PANC1 cells may be at least partially regulated by
the EGR1 transcription factor (Figure 3.32).
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Figure 3.32 Depletion of EGR1 with siRNA lead to suppressed NPTX1
expression in PANC1 LM3 cells. PANC1 LM3 cells were directly transfected
with two independent siRNA against the transcriptional factor EGR1.
NPTX1 and EGR1 expression level was determined by qRT-PCR 5 days post
transfection. ***p<0.001 using 1-sides student’s t test. **p<0.01 using 1-sides
student’s t test. *p<0.05 using 1-sides student’s t test.
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Summary of Chapter III
In Chapter III, I sought to identify novel metastasis regulators in pancreatic
cancer by first establishing both xenograft and syngeneic mouse model systems
by using in vivo selection. The human PANC1 and murine KPC pancreatic cancer
cell lines were selected for their outgrowth in the livers of mice. After two to
three rounds of in vivo selection, PANC1 LM3 and KPC LM2 cells were isolated
and their metastatic and orthotopic tumor growth capabilities were evaluated.
The in vivo selected PANC1 LM3 and KPC LM2 cells exhibited decreased
proliferation in vitro, but increased multi-organ metastatic and orthotopic tumor
growth capabilities in vivo, demonstrating that in vivo selected tumor cells had
specific growth and/or survival advantages in the tumor microenvironment.
In order to characterize the molecular programs that highly metastatic PANC1
LM3 and KPC LM2 cells utilized to promote cancer progression, I performed
transcriptomic profiling comparing the in vivo selected, highly metastatic
derivatives to their respective parental cells. RNA sequencing revealed 12
commonly de-regulated genes in both systems. Among the commonly deregulated genes, Neuronal Pentraxin 1 (NPTX1) was ranked first by the average
P-value between the two systems. NPTX1 is a secreted glycoprotein first
identified in the nervous system. It is involved in the synapse formation and
hypoxia induced apoptosis in the neurons, and its role in cancer has not been
characterized.

To further study the role of NPTX1 in pancreatic cancer, I knocked-down NPTX1
expression in both the xenograft and syngeneic mouse pancreatic cancer models.
Suppression of NPTX1 gene expression in both systems led to decreased liver
metastatic colonization. In addition, knockdown of NPTX1 in both systems
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suppressed orthotopic metastasis from the pancreas to multiple distal organs.
Temporal suppression of NPTX1 after initial metastatic seeding in the liver also
decreased metastatic growth, showing that NPTX1 was important in the
progression of metastatic colonization. NPTX1 was also found to promote
subcutaneous tumor growth demonstrating NPTX1’s role in both distal organ
metastasis and tumor growth in pancreatic cancer. However, over-expression of
NPTX1 was not sufficient to promote metastasis most likely due to the nonphysiological high levels of the over-expressed NPTX1 protein and its inability to
form the correct oligomeric complex with other potential proteins.
After establishing the functional role of NPTX1 in promoting metastatic
colonization and orthotopic tumor growth, I next sought to characterize the
biochemical properties of this protein and its gene expression regulation in
pancreatic cancer. Like previously described in neurons, NPTX1 was also
secreted by pancreatic cancer cells and formed high molecular weight oligomers.
Its expression was partially regulated by DNA methylation and the
transcriptional factor EGR1. These mechanisms could be adopted by the highly
metastatic, in vivo selected tumor cells to increase NPTX1 expression and
promote tumor growth and metastatic colonization in vivo.
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Chapter IV: Neuronal Pentraxin 1 Promotes Cancer Cell Proliferation in a
Hypoxic Tumor Microenvironment
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NPTX1 promotes cancer cell proliferation in the hypoxic pancreatic tumor
microenvironment.
To further investigate the cellular role of NPTX1 in promoting metastatic
progression and orthotopic tumor growth, I first asked if NPTX1 promotes cell
proliferation or inhibits cell death in vivo. In vitro, suppression of NPTX1
expression in the PANC1 LM3 cells result in no change in cell proliferation
(Figure 4.1). In vivo, NPTX1 knockdown in the PANC1 LM3 cells significantly
reduced the percentage of proliferating cells in liver metastatic nodules, as
assessed by Ki-67 staining of liver metastatic nodules and quantification (Figure
4.2). On the other hand, NPTX1 knockdown did not change the percentage of
cells undergoing apoptosis as measured by using a DEVD-luciferin system in
vivo , which assesses caspase 3/7 cleavage activity-mediated activation of
luciferin substrate and consequently luminescence (Figure 4.3).
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Figure 4.1 PANC1 LM3 cells with NPTX1 knockdown proliferate at the same
rate as control cells under standard cell culture condition in vitro. 8x10

4

PANC1 LM3 cells with NPTX1 knockdown and control cells were seeded at day
0. Cells were grown under standard cell culture condition and cell number was
counted at day 5.
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Figure 4.2 Ki-67 staining of liver metastasis sections from NSG mice
xenografted with PANC1 LM3 cells shows decreased proliferation when
NPTX1 expression is suppressed. Liver sections were made 14 days post
splenic injection of PANC1 LM3 shCTRL and PANC1 LM3 shNPTX1 cells.
***P<0.001 by 2-tail student’s t-test.
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Figure 4.3 In vivo apoptosis measured using a DEVD-luciferin system
shows no significant different between PANC1 LM3 cells with and
without knockdown of NPTX1. PANC1 LM3 cells with stable knockdown
of NPTX1 by a shCTRL and control cells were injected into the portal
circulation. Mice were imaged at day 14 and 21 using bioluminescence
imaging with both a regular luciferin (total luciferase signal) and a DEVD
luciferin that must be cleaved by caspase-3 and caspase-7 to be an active
substrate.
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After establishing NPTX1’s role in promoting cell proliferation in vivo but not in
vitro, I next investigated potential tumor microenvironmental conditions that
may differ from the in vitro cell culture condition. Pancreatic cancer is known to
be severely hypovascular and fibrotic with an extremely hypoxic tumor
microenvironment. Thus, I decided to investigate the extent of hypoxia in the
liver metastasis microenvironment in our metastasis model. To do that, I used the
chemical probe pimonidazole to detect areas with tissue oxygen tension lower
than 10mmHg in metastatic nodules in vivo. Pimonidazole becomes chemically
linked to tissues when the oxygen tension is lower than 10mmHg and can be
imaged using an antibody. In the liver metastasis sections derived from poorly
metastatic PANC1 parental cells, the tissue showed limited areas of hypoxia with
few proliferating cancer cells. However, the highly metastatic PANC1 LM3 cells
were highly proliferative in the liver even in a densely hypoxic tumor
microenvironment (Figure 4.4).
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Figure 4.4 PANC1 LM3 liver metastatic nodules are extensively hypoxic compared
to the parental PANC1 cells in vivo. The mouse livers were extracted 5 weeks post
5
splenic injection of the 3 x 10 PANC1 LM3 and PANC1 cells. The highly metastatic
PANC1 LM3 cells showed extensive hypoxic regions and the cancer cells were highly
proliferative despite the hypoxia. *P<0.05 by 2-tail student’s t-test.
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To determine if the highly metastatic PANC1 LM3 cells and the poorly
metastatic PANC1 cells had differential proliferative capabilities under low
oxygen or no oxygen condition in vitro, I conducted proliferation assay
comparing PANC1 LM3 cells to its parental PANC1 cells under normoxia,
hypoxia (0.5% oxygen), or anoxia (0% oxygen). In normoxia, the highly
metastatic PANC1 LM3 cells proliferated at a slower rate compared to the
parental PANC1 cells, as previously observed. However, under hypoxia for 5
days, the highly metastatic PANC1 LM3 cells proliferated at a faster rate
compared to the parental PANC1 cells. Under anoxia for 3 days, all of the lowly
metastatic PANC1 cells died while the highly metastatic PANC1 LM3 cells
proliferated at a slower rate (Figure 4.5). I concluded that the highly metastatic
PANC1 LM3 cells gained enhanced proliferating capability under low oxygen
environment.
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Figure 4.5 PANC1 LM3 cells proliferate faster under hypoxic and anoxic
condition compared to PANC1 cells. Highly metastatic PANC1 LM3 cells
proliferated at a slower rate in normoxia compared to PANC1 cells but could
proliferate at significant higher rate in hypoxia compared to the lowlymetastatic PANC1 cells. In anoxia for 72 hours, the lowly metastatic PANC1
cells detach completely from the tissue culture dish while the highlymetastatic PANC1 LM3 cells survive and proliferate. ***P<0.001 by 2-tail
student’s t-test.
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We further investigated if NPTX1 played any role in promoting cell proliferation
in a hypoxic environment. Indeed, highly metastatic PANC1 LM3 cells depleted
of NPTX1 by siRNA proliferated at slower rate compared to PANC1 LM3 cells
transduced with a control siRNA under hypoxia for 6 days (Figure 4.6). In
normoxia, depletion of NPTX1 in PANC1 LM3 cells did not significantly impact
proliferation relative to control cells (Figure 4.7). I then tested the impact of
modulating nutrients on the proliferative capacity of the metastatic cells, since
the tumor microenvironment is known to contain regions depleted of various
nutrients. NPTX1 knockdown in PANC1 LM3 cells also did not change
proliferation rates under low serum (2% FBS) or low glucose (1mg/mL)
conditions during normoxia (Figure 4.8 and 4.9). However, we cannot rule out
that under more stringent serum and glucose deprivation an effect could be
observed.
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Figure 4.6 NPTX1 promotes proliferation of PANC1 LM3 cells in hypoxia.
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Figure 4.7 PANC1 LM3 cells with suppressed NPTX1 expression
proliferate at the same rate under normoxia. NPTX1 expression was
transiently suppressed in PANC1 LM3 cells using two independent siRNA.
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Figure 4.8 PANC1 LM3 cells with suppressed NPTX1 expression proliferate at the
same rate under low serum (2% FBS) growth
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Figure 4.9 PANC1 LM3 cells with suppressed NPTX1 expression proliferate at the
same rate under low glucose (1mg/mL) growth condition
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Since NPTX1 is a secreted protein and can also potentially affect the infiltration of
cells into tumor microenvironment, I investigated its ability to modulate the
abundance of infiltrating stromal cells in the pancreatic cancer
microenvironment. In vivo, NPTX1 depleted PANC1 LM3 cells formed liver
metastatic nodules containing significantly fewer infiltrating myofibroblasts
compared to control PANC1 LM3 cells (Figure 4.10). To investigate if NPTX1 was
involved in recruitment of myofibroblasts, I co-injected the human hepatic
stellate cell line, Lx-2, with PANC1 LM3 cells with NPTX1 knockdown. Hepatic
stellate cells are the precursors of myofibroblasts in the liver. Co-injection of Lx-2
cells did not rescue the suppressed liver metastatic growth due to NPTX1
knockdown (Figure 4.11). These results suggest that either myofibroblasts are not
responsible for the NPTX1-mediated enhanced liver metastatic growth of
pancreatic cancer cells or that the Lx-2 cell line used for this experiment does not
behave in a similar manner as endogenous hepatic stellate cells in vivo.
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Figure 4.10 Knockdown of NPTX1 in cancer cells decreases infiltrating
myofibroblasts in the liver metastatic nodules. aSMA staining of liver
metastases sections from NSG mice xenografted with PANC1 LM3 cells shows
decreased myofibroblasts in the metastatic nodules when NPTX1 expression was
stably suppressed by shRNA. ***P<0.001 by 2-tail student’s t-test.
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Figure 4.11 Hepatic stellate cells do not rescue suppressed metastatic
5
growth due to NPTX1 knockdown in PANC1 LM3 cells. 1 x 10 human
5
hepatic stellate cells, Lx-2, were co-injected with 1 x 10 PANC1 LM3 cells
with NPTX1 knockdown or with control cells. Liver metastasis was
monitored via bioluminescence imaging at week 5. **P<0.01 by 2-tail
student’s t-test.
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Hepatic stellate cells are the precursors of myofibroblasts in the liver. During
fibrosis, hepatic stellate cells (HSCs) are activated and transdifferentiate into
myofibroblasts. During activation, HSC express increasing levels of the protein
alpha-Smooth Muscle Actin (aSMA). We investigated if NPTX1 could impact the
levels of myofibroblasts by activating primary murine hepatic stellate cells. In
vitro, recombinant NPTX1 did not activate murine primary hepatic stellate cells
but rather led to a slight decrease in murine aSMA expression (Figure 4.12).
Conditioned media from control PANC1 LM3 cells also did not activate murine
primary hepatic stellate cells greater than PANC1 LM3 cells depleted of NPTX1
(Figure 4.13). In vivo, knockdown of NPTX1 in PANC1 LM3 cells did not change
the abundance of infiltrated endothelial cells (Figure 4.14) or macrophages
(Figure 4.15) compared to the control in the xenograft mouse model. Nptx1
knockdown in KPC cells also did not alter the composition of infiltrating
immune cells including macrophages, neutrophils, B and T cells (Figure 4.16).
These experiments suggest that NPTX1 does not have a role on activating the
differentiation of HSC into myofibroblast.
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Figure 4.12 Recombinant human NPTX1 suppresses hepatic stellate cells
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Figure 4.13 Conditioned medium from PANC1 LM3 cells with or without
NPTX1 knockdown does not activate hepatic stellate cells in vitro.
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Figure 4.14 Knockdown of NPTX1 in PANC1 LM3 cells does not alter number
of endothelial cells in the liver metastatic nodules. Liver sections were made
14 days post splenic injection of PANC1 LM3 shCTRL and PANC1 LM3
shNPTX1 cells.
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Figure 4.15 Knockdown of NPTX1 in PANC1 LM3 cells does not alter number
of macrophages in the liver metastatic nodules. Liver sections were made 14
days post splenic injection of PANC1 LM3 shCTRL and PANC1 LM3 shNPTX1
cells.
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Figure 4.16 The immune cell infiltrates of KPC tumors with Nptx1
knockdown do not differ significantly from control. Liver metastases nodules
5
were harvested 10 days post splenic injection of 5 x 10 control and shRNA
mediated table Nptx1 knockdown KPC cells.
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Pancreatic cancer cells with high expression levels of NPTX1 exhibit a growth
advantage under a hypoxic microenvironment. Hypoxia-induced HIF1a response
is often activated by tumor cells adapting metabolically to the hypoxic tumor
micro-environment (Semenza, 2013). To investigate if this NPTX1-mediated
growth advantage was mediated through a HIF1a-dependent pathway, HIF1a
expression was suppressed using two independent siRNAs in the highly
metastatic PANC1 LM3 cells. Hypoxic proliferation assays of the PANC1 LM3
cells with HIF1a knockdown were performed and compared to control PANC1
LM3 cells. PANC1 LM3 cells with HIF1a knockdown did not proliferate slower
compared to PANC1 LM3 cells transfected with a control siRNA. These results
suggest that the effect of NPTX1 on cell survival under hypoxic conditions is not
mediated by HIF1a and thus potentially represent a novel mechanism the cancer
cells utilize to survive under low oxygen conditions.
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Figure 4.17 Proliferation of the highly metastatic PANC1 LM3 cells in
hypoxia is not affected by suppression of HIF1a. Knockdown of HIF1a in
PANC1 LM3 cells was generated using two independent siRNA. PANC1
LM3 cells with suppressed HIF1a and control cells were incubated in
hypoxia for 6 days and proliferation was measured by cell counting.
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Summary of Chapter IV
In Chapter IV, I investigated the cellular mechanisms of how NPTX1 promotes
pancreatic cancer metastasis and tumor growth. In vitro, NPTX1 depletion did
not alter pancreatic cancer cell proliferation. However, in vivo, knockdown of
NPTX1 in pancreatic cancer cells suppressed cancer cell proliferation in liver
metastases, demonstrating that NPTX1 promotes metastatic colonization and
orthotopic tumor growth in a tumor microenvironment-dependent manner.
Furthermore, NPTX1 suppression in pancreatic cancer cells did not alter cancer
cell apoptosis in vivo.

I next sought to uncover the potential features of the tumor microenvironment
that allowed pancreatic cancer cells expressing high level of NPTX1 to proliferate
rapidly in vivo. A hallmark of pancreatic cancer is its fibrotic and hypovascular
tumor environment leading to severe hypoxia. I found that the highly metastatic
PANC1 LM3 liver metastases with high NPTX1 levels had extensive hypoxic
regions compared to the poorly metastatic PANC1 tumors. In vitro, PANC1 LM3
cells grew more rapidly under hypoxia or anoxia compared to the parental
PANC1 cells. Knockdown of NPTX1 in the pancreatic cancer cells suppressed
proliferation under hypoxia, but not normoxia. Furthermore, this effect appears
independent of the canonical master transcriptional regulator of hypoxic
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response HIF1a. All of these findings suggest that NPTX1 may mediate its
proliferative effects through a novel mechanism during oxygen deprivation.

In addition to NPTX1’s role in promoting cancer cell proliferation under hypoxia,
I wondered if as a secreted protein, NPTX1 could affect other cell types in the
tumor microenvironment. In the PANC1 LM3 cells with suppressed NPTX1
expression, less myofibroblats were observed to have infiltrated into tumor
nodules. However, co-injecting myofibroblasts precursor cells, the hepatic stellate
cells, did not rescue the suppressed liver metastasis phenotype caused by NPTX1
depletion. Furthermore, recombinant NPTX1 or conditioned medium from
PANC1 LM3 did not activate hepatic stellate cells in vitro. Thus, NPTX1 may not
directly affect infiltrating myofibroblasts but rather may provide the cancer cells
a growth advantage under the hypoxic tumor environment that in term can
modulate phenotypes of stromal cells.
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Chapter V: Clinical Relevances of Neuronal Pentraxin 1
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NPTX1 is secreted by patient derived pancreatic cancer cells and can be detected
in the plasma of tumor bearing mice.
NPTX1 is a secreted protein with a signal peptide and could be detected
by western blot in the extracellular medium of the highly metastatic PANC1 LM3
cells at a higher level relative to the lowly metastatic PANC1 cells as shown
previously in Figure 3.27.

To determine the clinical relevance of NPTX1 in

pancreatic cancer, we examined the expression levels of NPTX1 in autopsy
samples of pancreatic tumors compared to normal pancreas obtained through a
collaboration with Dr. Christine Iacobuzio-Donahue at Memorial Sloan Kettering
Cancer Center. As previously described, under non-diseased conditions, NPTX1
was not observed to be expressed in the pancreas. In contrast to this, however, I
observed that multiple pancreatic tumors expressed NPTX1 mRNA as assessed
by qRT-PCR (Figure 5.1). On average, NPTX1 was expressed at more than 1000fold higher levels in pancreatic cancer samples relative to normal pancreas
samples. Moreover, NPTX1 was also expressed at relatively high level in clinical
pancreatic tumor samples compared to other types of tumors (Figure 5.2). In
several primary patient-derived pancreatic cancer cell lines, NPTX1 mRNA was
expressed at comparable levels to the highly metastatic PANC1 LM3 cells (Figure
5.3) and was detectable in the extracellular media at the protein level by western
blot (Figure 5.4).
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Figure 5.2 Pancreatic cancer tumors express NPTX1 at the mRNA level.

RNA sequencing of primary tumors from patients reveals that NPTX1 was

expressed at the mRNA level in clinical pancreatic cancer samples. Data

source: cBioPortal 2017
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Since NPTX1 is a secreted protein, we examined the abundance of NPTX1
in the plasma of mice bearing PANC1 LM3 xenografted tumors versus healthy
controls injected with PBS. In the tumor bearing mice, I was able to detect NPTX1
protein in the plasma of the mice at significantly higher levels (more than 17
folds) compared to healthy controls by using a commercially available ELISA kit
(Figure 5.5). Pancreatic cancer remains a lethal malignancy partially due to the
late diagnosis of this disease. These experiments suggest that NPTX1 can
potentially serve as an early routine diagnostic marker detectable by an ELISAbased blood test.

A.
PANC1

PANC1
LM3

Patient-derived
cell lines

Total secreted proteins

Figure 5.4 Pancreatic cancer cell lines secrete NPTX1 protein into the
extracellular space. Pancreatic cancer cell lines were incubated in serum free
medium for 16 hours. Extracellular medium was collected and concentrated
from the cell lines PANC1, PANC1 LM3, and four patient derived cell lines
(A13A primary, A6L liver met, 2.1 Lv met, A38.44 Lv met). Ponceau red stain
was used to visualize total secreted protein in the extracellular medium.
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Figure 5.5 NPTX1 is detected in the plasma of the pancreatic cancer mouse
5
xenograft model. 3 x 10 PANC1 LM3 cells or PBS was injected into the
portal circulation through the spleen to NSG mice. Plasma of the mice were
collected at week 5 and NPTX1 protein level was measured by ELISA.
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Summary of Chapter V
NPTX1 was previously described to be exclusively expressed in the nervous
system (Schlimgen et al., 1995). Through unbiased transcriptomic profiling, I
found that the highly metastatic PANC1 LM3 cells express and secrete NPTX1
into the extracellular space at high levels compared to their less metastatic
PANC1 parental cells. In Chapter V, I investigated NPTX1 expression in clinical
pancreatic cancer samples. Compared to normal pancreas, NPTX1 was highly
expressed by pancreatic cancers. In multiple patient-derived pancreatic cancer
primary cell lines, NPTX1 protein could also be detected in the extracellular
media.

NPTX1 is a secreted protein and it could be detected in the plasma of mice
bearing xenografted pancreatic cancers by ELISA but not in healthy controls.
Thus, these results demonstrate that NPTX1 may potentially serve as a
diagnostic marker for early detection of pancreatic cancer.
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Chapter 6 Summary and General Discussions
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Pancreatic cancer is a deadly disease because it is usually diagnosed at an
advanced stage and does not respond to current treatments. In the United States,
each year about 43,000 patients die from pancreatic cancer and it is the fourth
leading cause of cancer death. More than 80% of patients present with metastatic
disease at the time of diagnosis (Stathis and Moore, 2010) and metastatic
pancreatic adenocarcinoma has a median survival of eight to eleven months
under current standard of care (Ryan et al., 2014). Efforts in using other agents to
treat pancreatic cancer have mostly been fruitless and more than twenty Phase III
clinical trials have failed. The dismal survival outcome of this disease and lack of
success in clinical trials indicate the necessity for new models and improved
approaches toward therapies. Understanding the cellular and physiological basis
of metastatic pancreatic cancer is therefore of great interest to the medical and
scientific community with regard to developing new targeted therapies and
diagnostic biomarkers.

This thesis presents an effort to discover novel metastasis regulators in pancreatic
cancer using an unbiased and systematic approach: in vivo selection of both
xenograft and syngeneic murine models of pancreatic cancer combined with
transcriptomic profiling. Using the syngeneic and xenograft mouse models
allowed in vivo selection to be performed under both immunocompetent and
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immunodeficient backgrounds and accounted for potential molecular programs
that may regulate the immune component of metastasis. In vivo selected cells
derived from both the xenograft and syngeneic models successfully established
liver metastases. Unbiased and systematic transcriptomic profiling of the in vivo
selected and highly metastatic cancer cells compared to their poorly metastatic
parental cells revealed multiple commonly de-regulated genes as potential
metastasis regulators in pancreatic cancer. Among all the 12 candidate genes,
Neuronal Pentraxin 1 (NPTX1) was the most significantly up-regulated gene
ranked by average P-value in both highly metastatic in vivo selected populations
of the xenograft and syngeneic models compared to their respective, lowly
metastatic parental populations.

NPTX1 was first described to be exclusively expressed by neurons (Schlimgen et
al., 1995). Subsequent studies revealed NPTX1’s role in synaptic plasticity by
modulating AMPA receptor formation (Bjartmar et al., 2006; Sia et al., 2007; Xu et
al., 2003). In synapses, NPTX1 forms high-molecular weight oligomers with the
other members of the neuronal pentraxin family proteins, Neuronal Pentraxin-2
and Neuronal Pentraxin Receptor (NPTXR) to modulate the formation of AMPA
receptors. In addition to NPTX1’s role in synaptic plasticity, several reports also
suggested that NPTX1 may play a role in hypoxia induced neuronal damage (Al
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Rahim and Hossain, 2013; Hossain et al., 2004). NPTX1 is a 47kDa secreted
glycoprotein that belongs to the pentraxin protein family (Xu et al., 2003). The
pentraxin protein family includes acute phase proteins such as C-reactive protein
(CRP) and Serum Amyloid P proteins (SAP). Many members of the pentraxin
family are pattern recognition receptors involved in innate immunity (Du Clos,
2013) and the canonical receptors of pentraxin proteins are Fc receptors
(Bodman-Smith et al., 2002). Because NPTX1 was previously thought to be
exclusively expressed in the neurons, its binding affinity to Fc receptors was
never characterized. While there is one report indicating altered methylation
status in the NPTX1 promoter in lung cancer (Zhou et al., 2015), the functional
role of NPTX1 in cancer remains elusive.

Because NPTX1 was highly expressed by both the syngeneic and xenograft in
vivo selected, highly metastatic pancreatic cancer cells, I hypothesized that
NPTX1 promotes pancreatic cancer progression. To reveal the role of NPTX1 in
pancreatic cancer, I employed both syngeneic and xenograft pancreatic cancer
mouse models to study functional roles of NPTX1 in pancreatic cancer
progression. These functional studies established NPTX1 as both a promoter of
metastatic colonization and orthotopic tumor growth in pancreatic cancer in vivo.
Specifically, NPTX1 promoted cancer cell proliferation in vivo, but had no effect
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on apoptosis. Importantly, NPTX1 promoted pancreatic cancer metastatic
progression in the liver even after macro-metastases establishment. The
mechanism of macro-metastases colonization is poorly understood compared to
earlier steps of metastasis such as intravasation. However, macro-metastases
colonization is clinically important because most pancreatic cancer patients
present with established distal organ metastasis, and targeted therapies that
suppress progression of macro-metastatic disease may serve potential
therapeutic benefits.

Because NPTX1 expression outside of the nervous system was not previously
described in the literature, biochemical characterization of NPTX1 in pancreatic
cancer cells was performed. Similar to neurons, pancreatic cancer cells secrete
NPTX1 into the extracellular space forming high-molecular weight oligomers.
Investigations into the gene expression regulation of NPTX1 in pancreatic cancer
revealed that NPTX1 is partially regulated by epigenetic modifications and a
transcription factor, EGR1.

While loss-of-function liver metastatic colonization assays and orthotopic tumor
growth studies revealed NPTX1’s role in promoting pancreatic cancer
progression, gain-of-function assays in vivo did not lead to increased metastasis
nor did they rescue suppressed metastatic growth due to NPTX1 knockdown in
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cancer cells. One potential explanation is the non-physiologic level of NPTX1
expressed using the over-expression construct. NPTX1 can form heterooligomers with the other neuronal pentraxin proteins in neurons (Xu et al., 2003),
and it is possible that the stoichiometry of the over-expressed NPTX1 was nonfunctional. Indeed, over-expressing NPTX1 in the PANC1 LM3 cells with NPTX1
knockdown led to further suppression of liver metastasis relative to cells overexpressing GFP, demonstrating that the over-expressed NPTX1 may exert
dominant negative effects.

Interestingly, while NPTX1 depletion in pancreatic cancer cells dramatically
decreased liver metastatic colonization in the xenograft and syngeneic mouse
models, NPTX1 depletion did not lead to obvious cellular phenotypic changes in
vitro and did not affect cell proliferation under standard cell culture conditions.
Similarly, the in vivo selected, highly metastatic PANC1 LM3 or KPC LM2 cells
proliferated much faster compared to their respective parental cells in vivo, but
proliferated slower compared to the parental cells in vitro. The difference
between the in vitro and in vivo tumor cell proliferation indicated the importance
of the tumor microenvironment.

One hallmark of pancreatic cancer is the hypoxic tumor microenvironment. In
the in vivo liver metastatic colonization model, the in-vivo selected, highly
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metastatic pancreatic cancer cells were capable of continued proliferation even
after experiencing extensive hypoxia in the tumor microenvironment. Indeed, the
in vivo selected, highly metastatic pancreatic cancer cells proliferated at
significantly higher rates relative to the lowly metastatic parental cells in hypoxia
in vitro.

Suppression of NPTX1 also specifically lowered pancreatic cancer cell
proliferation under hypoxia, but not in normoxia. Hypoxia-induced HIF1a
response is often activated by tumor cells for hypoxic and metabolic adaptation
(Semenza, 2013). However, knockdown of HIF1a did not lead to changes in the
proliferation rate of the in vivo selected and highly metastatic pancreatic cancer
cells, indicating that these highly metastatic cancer cells utilize alternative
mechanisms to promote increased proliferation in hypoxia. Further studies on
the molecular mechanisms of how NPTX1 can promotes pancreatic cancer
survival in hypoxia can provide important insights into the progression
mechanisms of metastatic pancreatic cancer. Since NPTX1 is a secreted protein,
the identification of its receptor and its extracellular roles in cancer will be an
interesting topic for future investigations.

While NPTX1 can promote cell proliferation in hypoxia, since is it a secreted
protein, it could potentially have non-cell autonomous roles in the tumor
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microenvironment as well. Cellular components including myofibroblasts,
endothelial cells, and immune cells were examined. Suppression of NPTX1 in
cancer cells led to decreased infiltrating myofibroblasts, while recombinant
NPTX1 and cancer conditioned medium were insufficient to activate the stellate
cells (precursors of the myofibroblasts), suggesting that NPTX1 is unlikely to
directly interact with the myofibroblasts. Rather, high NPTX1 expression could
provide proliferative advantages to cancer cells within a hypoxic
microenvironment and this environment in term may influence the survival or
growth of stromal cells. For example, hepatic stellate cells have been shown to
activate and transdifferentiate into myofibroblasts in hypoxia (Shi et al., 2007).

NPTX1 depletion did not change the number of endothelial cells or immune cells
in the xenograft or syngeneic models. However, only relative numbers of
immune cells were profiled and it is possible that NPTX1 depletion may lead to
differential polarization of immune cells, such as macrophages. Given the
pentraxin family protein’s role in innate immunity, further investigations on
NPTX1’s effector cell types and potential receptors outside of the nervous system
will elucidate previously unknown functions of this gene in cancer.

Analysis of NPTX1 expression revealed that NPTX1 is specifically expressed by
pancreatic tumors but not in healthy pancreatic tissues. In addition, NPTX1 is
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secreted by pancreatic cancer cells into the extracellular space and is detectable in
the plasma of the xenografted pancreatic cancer mouse model. NPTX1 could
potentially serve as a diagnostic marker in pancreatic cancer and clinical studies
examining NPTX1 level in pancreatic patients’ sera may provide further insights.
Furthermore, NPTX1 knockout mice (Bjartmar et al., 2006) are grossly healthy.
NPTX1’s secreted status, role in promoting metastasis progression, and a lack of
disease phenotype in the mouse knockout model suggest that NPTX1 could
potentially be an attractive therapeutic target. Developing a neutralizing
antibody is one possible strategy to specifically inhibit NPTX1 and may serve as
potential future targeted therapy in pancreatic cancer.
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